<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="research-article" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">t5HQYqt97zKc6wPfxQFscxh</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2022001100691</article-id>
      <article-id pub-id-type="publisher-id">abc.20211055</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20211055</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estrat&#233;gia F&#225;rmaco-Invasiva no Infarto do Mioc&#225;rdio: An&#225;lise Descritiva, Apresenta&#231;&#227;o de Sintomas Isqu&#234;micos e Preditores de Mortalidade</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6746-8327</contrib-id>
          <name>
            <surname>Bianco</surname>
            <given-names>Henrique Tria</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-4295-9151</contrib-id>
          <name>
            <surname>Povoa</surname>
            <given-names>Rui</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-5738-2623</contrib-id>
          <name>
            <surname>Izar</surname>
            <given-names>Maria Cristina</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alves</surname>
            <given-names>Claudia Maria Rodrigues</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Adriano Henrique Pereira</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9603-6072</contrib-id>
          <name>
            <surname>Bombig</surname>
            <given-names>Maria Teresa Nogueira</given-names>
          </name>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gon&#231;alves</surname>
            <given-names>Iran</given-names>
            <suffix>Jr</suffix>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luna</surname>
            <given-names>Br&#225;ulio</given-names>
            <suffix>Filho</suffix>
          </name>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aguirre</surname>
            <given-names>Ana Caroline</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moraes</surname>
            <given-names>Pedro Ivo de Marqui</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2178-1518</contrib-id>
          <name>
            <surname>Almeida</surname>
            <given-names>Dirceu</given-names>
          </name>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreira</surname>
            <given-names>Fl&#225;vio Tocci</given-names>
          </name>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Reda&#231;&#227;o do manuscrito</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9774-4406</contrib-id>
          <name>
            <surname>Povoa</surname>
            <given-names>Fernando Focaccia</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stefanini</surname>
            <given-names>Edson</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caixeta</surname>
            <given-names>Adriano Mendes</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise estat&#237;stica</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bacchin</surname>
            <given-names>Amanda S.</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mois&#233;s</surname>
            <given-names>Valdir Ambr&#243;sio</given-names>
          </name>
          <role>Obten&#231;&#227;o de dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9911-4598</contrib-id>
          <name>
            <surname>Fonseca</surname>
            <given-names>Francisco A.H.</given-names>
          </name>
          <role>Concep&#231;&#227;o e desenho da pesquisa</role>
          <role>Obten&#231;&#227;o de dados</role>
          <role>An&#225;lise e interpreta&#231;&#227;o dos dados</role>
          <role>Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante</role>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
          <institution content-type="orgdiv1">Cardiologia</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal de S&#227;o Paulo &#8211; Cardiologia, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution content-type="orgname">Universidade Federal de S&#227;o Paulo Escola Paulista de Medicina</institution>
          <institution content-type="orgdiv1">Medicina</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal de S&#227;o Paulo Escola Paulista de Medicina &#8211; Medicina, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><bold>Correspond&#234;ncia: Henrique Tria Bianco</bold> &#8226; Universidade Federal de S&#227;o Paulo - Rua Loefgren, 1350. CEP - <postal-code>04040-001</postal-code>, S&#227;o Paulo, SP - Brasil E-mail: <email>henriquetria@uol.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>
            <bold>Potencial conflito de interesse</bold>
          </p>
          <p>N&#227;o h&#225; conflito com o presente artigo</p>
        </fn>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>25</day>
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <pub-date publication-format="electronic" date-type="collection">
        <month>11</month>
        <year>2022</year>
      </pub-date>
      <volume>119</volume>
      <issue>5</issue>
      <fpage>691</fpage>
      <lpage>702</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>01</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>04</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>06</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Resumo</title>
        <sec>
          <title>Fundamento</title>
          <p>O infarto do mioc&#225;rdio com eleva&#231;&#227;o do segmento-ST (IAMCSST) &#233; definido por sintomas acompanhados por altera&#231;&#245;es t&#237;picas do eletrocardiograma. Entretanto, a caracteriza&#231;&#227;o dos sintomas isqu&#234;micos n&#227;o &#233; clara, principalmente em subgrupos, como mulheres e idosos.</p>
        </sec>
        <sec>
          <title>Objetivos</title>
          <p>Analisar a tipifica&#231;&#227;o dos sintomas isqu&#234;micos, m&#233;tricas temporais e observar a ocorr&#234;ncia de desfechos intra-hospitalares, em an&#225;lise dos escores preditivos, em pacientes com IAMCSST, em estrat&#233;gia f&#225;rmaco-invasiva.</p>
        </sec>
        <sec>
          <title>M&#233;todos</title>
          <p>Estudo envolvendo 2.290 pacientes. Tipos de apresenta&#231;&#245;es cl&#237;nicas pr&#233;-definidas: dor t&#237;pica, dor at&#237;pica, dispn&#233;ia, sincope. Medimos o tempo entre o in&#237;cio dos sintomas &#224; demanda pelo atendimento e o intervalo entre a chegada &#224; unidade-m&#233;dica e tromb&#243;lise. <italic>Odds-ratios</italic> (OR; IC-95%) foram estimadas em modelo de regress&#227;o. Curvas ROCs foram constru&#237;das para preditores de mortalidade. N&#237;vel de signific&#226;ncia adotado (alfa) foi de 5%.</p>
        </sec>
        <sec>
          <title>Resultados</title>
          <p>Mulheres apresentaram alta preval&#234;ncia de sintomas at&#237;picos; maior tempo entre o in&#237;cio dos sintomas e a procura por atendimento; atraso entre a chegada ao pronto-socorro e a fibrin&#243;lise. A mortalidade hospitalar foi de 5,6%. Predi&#231;&#227;o de risco pela classifica&#231;&#227;o Killip-Kimball: AUC: [0,77 (0,73-0,81)] em classe &#8805;II. Subgrupos estudados [OR (IC-95%)]: mulheres [2,06 (1,42-2,99); p=0,01]; insufici&#234;ncia renal cr&#244;nica [3,39 (2,13-5,42); p&lt;0,001]; idosos [2,09 (1,37-3,19) p&lt;0,001]; diab&#233;ticos [1,55 (1,04-2,29); p=0,02]; obesos 1,56 [(1,01-2,40); p=0,04]; acidente vascular cerebral pr&#233;vio [2,01 (1,02-3,96); p=0,04] correlacionaram-se com maiores taxas de mortalidade.</p>
        </sec>
        <sec>
          <title>Conclus&#227;o</title>
          <p>Apesar das mais altas taxas de mortalidade em alguns subgrupos, disparidade significativa persiste nas mulheres, com atrasos no reconhecimento dos sintomas e tromb&#243;lise imediata. Destaca-se a aplicabilidade do escore Killip-Kimball na predi&#231;&#227;o, independentemente da apresenta&#231;&#227;o cl&#237;nica.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Infarto do Mioc&#225;rdio por Supradesnivelamento do Segmento ST</kwd>
        <kwd>S&#237;ndrome Coron&#225;riana Aguda</kwd>
        <kwd>Interven&#231;&#227;o Coron&#225;ria Percut&#226;nea/m&#233;todos</kwd>
        <kwd>Terapia Trombol&#237;tica/m&#233;todos Angina Pectoris</kwd>
        <kwd>Hospitaliza&#231;&#227;o</kwd>
        <kwd>Mortalidade</kwd>
      </kwd-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="8"/>
        <equation-count count="0"/>
        <ref-count count="38"/>
        <page-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>Apesar dos avan&#231;os nas abordagens de reperfus&#227;o, o infarto agudo do mioc&#225;rdio continua a ser a principal causa de morte em todo o mundo. Seu diagn&#243;stico &#233; considerado quando se pode detectar altera&#231;&#245;es t&#237;picas do eletrocardiograma (ECG) e/ou a eleva&#231;&#227;o de marcadores, especialmente as troponinas, que recebem cada vez mais aten&#231;&#227;o como marcadores espec&#237;ficos de inj&#250;ria mioc&#225;rdica. O infarto do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST) geralmente &#233; causado por oclus&#227;o coron&#225;ria aguda, secund&#225;ria &#224; ruptura de placa e trombose, e requer a interven&#231;&#227;o precoce.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Portanto, o controle do IAMCSST deve ser realizado o mais r&#225;pido poss&#237;vel para evitar maiores les&#245;es ao mioc&#225;rdio e diminuir o risco de complica&#231;&#245;es e mortalidade. Embora a interven&#231;&#227;o coron&#225;ria percut&#226;nea (ICP) seja considerada o &#8220;padr&#227;o-ouro&#8221; de tratamento, ela n&#227;o est&#225; suficientemente dispon&#237;vel, especialmente nos pa&#237;ses em desenvolvimento. O estudo STREAM valoriza uma estrat&#233;gia de reperfus&#227;o combinando terapia fibrinol&#237;tica e transfer&#234;ncia imediata a um centro terci&#225;rio, para a realiza&#231;&#227;o da ICP de resgate em pacientes que n&#227;o respondem &#224; fibrin&#243;lise, bem como uma angiografia diagn&#243;stica precoce e uma ICP secund&#225;ria no per&#237;odo de 24 horas ap&#243;s a tromb&#243;lise.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Entretanto, alguns fatores podem influenciar a demora em procurar assist&#234;ncia emergencial, tais como a percep&#231;&#227;o e o reconhecimento de sintomas isqu&#234;micos agudos. A interpreta&#231;&#227;o de sinais de alerta &#233; o gatilho que leva os pacientes a buscar a assist&#234;ncia m&#233;dica, devido &#224; gravidade dessa condi&#231;&#227;o potencialmente fatal. Em contraste, a dor deve ser vista como um fen&#244;meno multidimensional que envolve aspectos fisiol&#243;gicos, sensoriais e socioculturais, e pode ser afetado por expectativas dentro de um contexto cultural.</p>
      <p>A estratifica&#231;&#227;o dos riscos permite aos prestadores identificar o n&#237;vel certo de cuidado e servi&#231;os para subgrupos de pacientes distintos. Ela &#233; o processo de atribuir um status de risco e, em seguida, usar esse relat&#243;rio para orientar sobre que cuidado &#233; oferecido para melhorar os desfechos gerais de sa&#250;de. No entanto, durante o processo diagn&#243;stico de infarto do mioc&#225;rdio, com base em relat&#243;rios cl&#237;nicos e crit&#233;rios de ECG, podem surgir diferen&#231;as em rela&#231;&#227;o a como os sintomas s&#227;o tratados, especialmente em subgrupos espec&#237;ficos, tais como grupos de mulheres ou de pessoas mais idosas, apresentando evid&#234;ncias e relev&#226;ncia de recanaliza&#231;&#227;o precoce, cujos benef&#237;cios se tornam mais discretos ou at&#233; inexistentes na reperfus&#227;o tardia.<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup> Al&#233;m disso, ainda h&#225; controv&#233;rsias e interesses especiais em rela&#231;&#227;o ao desempenho de preditores de mortalidade precoces em pacientes que passaram por tratamento trombol&#237;ticos em uma abordagem f&#225;rmaco-invasiva. Portanto, o presente estudo considerou a avalia&#231;&#227;o estratificada de sintomas isqu&#234;micos, fundamentalmente associados a m&#233;tricas temporais, incluindo o tempo entre o aparecimento dos sintomas e a busca por tratamento m&#233;dico, as necessidades m&#233;dicas do paciente entre a chegada &#224; unidade de emerg&#234;ncia e o reconhecimento da condi&#231;&#227;o aguda, com o in&#237;cio imediato dos protocolos de reperfus&#227;o. No cen&#225;rio da estrat&#233;gia f&#225;rmaco-invasiva, pode-se tamb&#233;m especular sobre poss&#237;veis diferen&#231;as na forma em que os sintomas apareceram e os tempos pivotais em alguns subgrupos, considerando o impacto da reperfus&#227;o tardia em desfechos cl&#237;nicos relevantes.</p>
      <p>Dessa forma, nosso estudo teve o objetivo de examinar as associa&#231;&#245;es entre a apresenta&#231;&#227;o de sintomas isqu&#234;micos e fatores de risco com os desfechos cardiovasculares em uma coorte de pacientes com IAMCSST durante o per&#237;odo de hospitaliza&#231;&#227;o, bem como realizar uma an&#225;lise precisa das classifica&#231;&#245;es de previs&#227;o de risco.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todos</title>
      <sec>
        <title>Desenho do estudo e declara&#231;&#245;es &#233;ticas</title>
        <p>Estudo prospectivo e observacional, com um tamanho de amostra definido por conveni&#234;ncia, envolvendo 2.290 pacientes com IAMCSST que foram admitidos consecutivamente internados em um hospital universit&#225;rio na cidade de S&#227;o Paulo, Brasil. Todos os pacientes foram inicialmente submetidos a terapia trombol&#237;tica com tenecteplase (TNK) em unidades hospitalares e centros de cuidado prim&#225;rios e, em seguida, encaminhados &#224; angiografia coron&#225;ria. Quando apropriado, foram realizadas interven&#231;&#245;es coron&#225;rias percut&#226;neas no per&#237;odo de 24 horas ap&#243;s a fibrin&#243;lise, ou imediatamente, se houvesse a necessidade de tratamento de resgate. Este estudo est&#225; de acordo com a Declara&#231;&#227;o de Helsinki, o comit&#234; de &#233;tica local aprovou o protocolo de pesquisa, e o consentimento informado foi obtido de todos os pacientes ou seus guardi&#245;es legais. O estudo est&#225; registrado em ClinicalTrials.gov (NCT02090712).</p>
      </sec>
      <sec>
        <title>Estrat&#233;gia f&#225;rmaco-invasiva</title>
        <p>A estrat&#233;gia f&#225;rmaco-invasiva &#233; definida pelo tratamento de fibrin&#243;lise com um bolus intravenoso de TNK, com uma dose ajustada pelo peso, seguida de cateterismo card&#237;aco no per&#237;odo de 24 horas, mesmo em pacientes est&#225;veis com reperfus&#227;o bem-sucedida, com a inten&#231;&#227;o de tratar a les&#227;o culpada. Ap&#243;s os resultados do estudo STREAM em junho de 2013, os pacientes com mais de 75 anos de idade receberam meia dose de tenecteplase (1/2 TNK). No diagn&#243;stico, os pacientes receberam &#225;cido acetilsalic&#237;lico e clopidogrel conforme recomendado pelas diretrizes.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> As angioplastias de resgate foram indicadas pela equipe m&#233;dica local, devido a tromb&#243;lise ineficaz no tratamento da art&#233;ria relacionada ao infarto (ARI). O termo <italic>les&#227;o culpada</italic> foi usado para designar o vaso arterial respons&#225;vel pelos sintomas do paciente com IAMCSST. Na maioria dos casos, apenas as les&#245;es culpadas foram tratadas, ou seja, apenas les&#245;es em ARI foram tratadas diretamente por angioplastia e coloca&#231;&#227;o de stent. O presente estudo contou com um banco de dados centralizado, contendo um perfil demogr&#225;fico, dados cl&#237;nicos, ECGs, tratamentos, intervalos de tempo e eventos hospitalares. Portanto, todos os desfechos relevantes foram sistematicamente registrados e as taxas de mortalidade foram analisadas por observadores independentes.</p>
      </sec>
      <sec>
        <title>Defini&#231;&#245;es de apresenta&#231;&#245;es cl&#237;nicas</title>
        <p>A apresenta&#231;&#227;o cl&#237;nica de sintomas isqu&#234;micos agudos foi relatada pelos pacientes, e equipes treinadas analisaram os dados durante o per&#237;odo de interna&#231;&#227;o hospitalar.</p>
        <list list-type="order">
          <list-item>
            <p>Dor tor&#225;cica t&#237;pica: dor tor&#225;cica opressiva &#224; esquerda, que pode se irradiar para o membro superior esquerdo, de grande intensidade e prolongada (mais de 20 minutos), que n&#227;o melhorou ou teve al&#237;vio apenas parcial com repouso ou nitrato sublingual. A irradia&#231;&#227;o para mand&#237;bula, membro superior direito, dorso, ombros e epig&#225;strio tamb&#233;m foi considerada para essa apresenta&#231;&#227;o. Esse grupo incluiu pacientes com apresenta&#231;&#227;o concomitante de dispneia ou epis&#243;dio sincopal.</p>
          </list-item>
          <list-item>
            <p>Dor at&#237;pica: dor no quadrante superior direito ou regi&#227;o epig&#225;strica do abd&#244;men, dorsal, regi&#227;o mandibular ou outra regi&#227;o n&#227;o tor&#225;cica, referida como pontada, queima&#231;&#227;o de intensidade vari&#225;vel, dura&#231;&#227;o prolongada (maior que 20 minutos). Inclu&#237;dos nesse grupo estavam os pacientes com apresenta&#231;&#227;o concomitante de dispneia ou epis&#243;dios sincopais.</p>
          </list-item>
          <list-item>
            <p>Dispneia: foram inclu&#237;dos neste grupo os pacientes que n&#227;o relataram dor tor&#225;cica, mas que se queixaram de cansa&#231;o agudo ou piora desse sintoma nas &#250;ltimas horas. Foi considerada a experi&#234;ncia subjetiva de desconforto respirat&#243;rio, composta por sensa&#231;&#245;es qualitativamente diferentes e com intensidade vari&#225;vel.</p>
          </list-item>
          <list-item>
            <p>S&#237;ncope: foram considerados os pacientes que n&#227;o relataram dor tor&#225;cica, mas sim desmaio ou perda s&#250;bita e transit&#243;ria da consci&#234;ncia ou qualquer piora nas &#250;ltimas horas.</p>
          </list-item>
        </list>
      </sec>
      <sec>
        <title>Tempos pivotais medidos</title>
        <list list-type="order">
          <list-item>
            <p>Intervalo de tempo entre o in&#237;cio da dor tor&#225;cica persistente, ou outra queixa representativa de sintomas isqu&#234;micos, e a chegada do paciente &#224; unidade de sa&#250;de;</p>
          </list-item>
          <list-item>
            <p>Intervalo de tempo entre chegada &#224; unidade de sa&#250;de e tromb&#243;lise;</p>
          </list-item>
          <list-item>
            <p>Intervalo de tempo entre a tromb&#243;lise e a angiografia coron&#225;ria.</p>
          </list-item>
        </list>
      </sec>
      <sec>
        <title>Escores de previs&#227;o</title>
      </sec>
      <sec>
        <title>Preditores de risco usados durante a primeira consulta m&#233;dica</title>
        <list list-type="order">
          <list-item>
            <p>Classifica&#231;&#227;o Killip-Kimball (KK);<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
          </list-item>
          <list-item>
            <p>TIMI-Risk;<sup><xref ref-type="bibr" rid="B7">7</xref></sup></p>
          </list-item>
          <list-item>
            <p>Escore GRACE<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
          </list-item>
        </list>
      </sec>
      <sec>
        <title>Vari&#225;veis angiogr&#225;ficas</title>
        <p>Cardiologistas intervencionistas experientes realizaram an&#225;lises angiogr&#225;ficas pelo escore de fluxo [(TIMI- flow), perfus&#227;o coron&#225;ria epic&#225;rdica];<sup><xref ref-type="bibr" rid="B9">9</xref></sup> e [Myocardial Blush Grade (MBG), perfus&#227;o mioc&#225;rdica no n&#237;vel do tecido];<sup><xref ref-type="bibr" rid="B10">10</xref></sup> obtendo-se TIMI-flow e MBG antes e p&#243;s-interven&#231;&#227;o percut&#226;nea, quando aplic&#225;veis (chamados de escores iniciais e finais). Complica&#231;&#245;es inerentes ao procedimento tamb&#233;m foram relatadas. A estrat&#233;gia do procedimento (aspira&#231;&#227;o do trombo, dilata&#231;&#227;o do bal&#227;o, sele&#231;&#227;o do stent e regime de anticoagula&#231;&#227;o) foi deixada a crit&#233;rio do operador.</p>
      </sec>
      <sec>
        <title>An&#225;lise estat&#237;stica</title>
        <p>Este estudo buscou alcan&#231;ar uma coleta de dados prospectiva e consecutiva de uma grande popula&#231;&#227;o, em que pr&#225;ticas m&#233;dicas padr&#227;o atuais s&#227;o aplicadas em uma rede organizada. As vari&#225;veis cont&#237;nuas foram expressas como m&#233;dia &#177; desvio padr&#227;o (DP) ou mediana e faixa interquartil [FIQ (25&#186; - 75&#186; percentis)], de acordo coma normalidade dos dados. Para avaliar as suposi&#231;&#245;es de normalidade, usamos o teste D&#8217;Agostino-Pearson, desenvolvido para avaliar uma amostragem grande, e a confirma&#231;&#227;o foi feita pela inspe&#231;&#227;o visual de gr&#225;ficos de dispers&#227;o. Vari&#225;veis categ&#243;ricas foram descritas como frequ&#234;ncias absolutas e relativas, e examinadas pelo teste qui-quadrado de Pearson. Para compara&#231;&#245;es de vari&#225;veis num&#233;ricas entre grupos, usamos o teste t de Student n&#227;o pareado ou o teste U de Mann-Whitney quando a distribui&#231;&#227;o n&#227;o-Gaussiana foi considerada. As an&#225;lises de vari&#226;ncia simples pelo teste &#8220;t&#8221;, ou de seus equivalentes n&#227;o param&#233;tricos foram realizadas para a observa&#231;&#227;o da distribui&#231;&#227;o e da homocedasticidade dos valores. Para comparar propor&#231;&#245;es entre os grupos, o teste &#967;<sup><xref ref-type="bibr" rid="B2">2</xref></sup> (qui-quadrado) foi usado para amostras independentes. Para presumir uma igualdade de vari&#226;ncia entre os grupos, os ajustes foram feitos usando-se o teste de Levene. O risco relativo foi determinado pela raz&#227;o entre os portadores de determinada vari&#225;vel e os n&#227;o portadores. Para analisar a rela&#231;&#227;o de algumas vari&#225;veis categ&#243;ricas e os desfechos, elas foram transformadas em dicot&#244;micas. Portanto, o teste de propor&#231;&#227;o (qui-quadrado) foi usado para observar a independ&#234;ncia entre as univariadas para obter as raz&#245;es de chance (RC) em um modelo de correla&#231;&#227;o entre univariadas potencialmente preditivas e os desfechos. Na estat&#237;stica multivariada verificamos as rela&#231;&#245;es de m&#250;ltiplas vari&#225;veis, apenas para as com signific&#226;ncia na entrada (vari&#225;veis com p &lt;0,10), para a observa&#231;&#227;o de seu grau de independ&#234;ncia. Utilizamos o modelo de regress&#227;o log&#237;stica bin&#225;ria, pela t&#233;cnica de m&#225;xima verossimilhan&#231;a, em que a vari&#225;vel dependente era dicot&#244;mica e as vari&#225;veis preditoras inseridas pelo modelo <italic>stepwise</italic>, considerando a aus&#234;ncia de colinearidade pelo &#237;ndice VIF (fator de infla&#231;&#227;o da vari&#226;ncia), com a qualidade do ajuste avaliada pelo diagrama de Hosmer-Lemeshow. As vari&#225;veis preditoras foram analisadas simultaneamente, de forma que o efeito de cada vari&#225;vel foi ajustado para ter um efeito nas demais. Esse modelo de regress&#227;o adiciona sistematicamente a vari&#225;vel mais significativa ou remove a vari&#225;vel menos significativa durante cada etapa. O &#237;ndice <bold>&#945;</bold> de Crombach-padronizado foi usado para calcular a confiabilidade dos escores angiogr&#225;ficos TIMI-flow e MBG estimados pelos operadores m&#233;dicos.</p>
        <p>As curvas de caracter&#237;stica de opera&#231;&#227;o do receptor (ROC) foram constru&#237;das para determinar a sensibilidade e a especificidade dos escores de predi&#231;&#227;o de desfechos hospitalares. A forma da curva ROC e a &#225;rea sob a curva (AUC) ajudaram a estimar o n&#237;vel de poder discriminativo de um teste. Um teste diagn&#243;stico perfeito tem uma AUC de 1,0, enquanto um teste n&#227;o discriminat&#243;rio tem uma &#225;rea de 0,5. Outras an&#225;lises tamb&#233;m foram aplicadas, considerando as raz&#245;es de probabilidade na previs&#227;o de eventos. Portanto, com base nas raz&#245;es de probabilidade, a raz&#227;o de chance diagn&#243;stica (RCD), uma m&#233;trica global de precis&#227;o diagn&#243;stica, foi calculada, ou seja, a raz&#227;o de chance de positividade em sujeitos com o desfecho para a chance em sujeitos sem o desfecho. Consideramos o valor de p&lt;0,05 como estatisticamente significativo, em testes bicaudais. As an&#225;lises foram realizadas usando SPSS-vers&#227;o-20 (IBM-SPSS Statistics, EUA)<sup>&#174;</sup>.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <sec>
        <title>Caracter&#237;sticas cl&#237;nicas e epidemiol&#243;gicas</title>
        <p>A <xref ref-type="table" rid="t1">Tabela 1</xref> mostra que os pacientes tinham uma mediana (FIQ) de 58 (50-65) anos de idade, e aproximadamente 70% eram homens. A maioria dos pacientes era hipertenso e fumante, e aproximadamente um ter&#231;o deles tinha diabetes. Uma pequena propor&#231;&#227;o dos pacientes teve eventos anteriores, tais como infarto do mioc&#225;rdio, revasculariza&#231;&#227;o cir&#250;rgica ou percut&#226;nea, e acidente vascular cerebral pr&#233;vio. O grupo mais velho tinha &#8805;60 anos de idade. Os preditores de risco inclu&#237;am dados sobre o hist&#243;rico m&#233;dico do paciente e os fatores de risco, que foram analisados durante a admiss&#227;o hospitalar. Este estudo tamb&#233;m apresenta dados sobre vari&#225;veis hemodin&#226;micas obtidas na emerg&#234;ncia, tais como dados laboratoriais (necrose e marcadores bioqu&#237;micos) (<xref ref-type="table" rid="t2">Tabela 2</xref>).</p>
        <table-wrap id="t1">
          <label>Tabela 1</label>
          <caption>
            <title>Caracter&#237;sticas da linha de base da coorte estudada</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="50%">
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF">
                <th style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Vari&#225;veis</th>
                <th style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#76B4CF">
                <th align="left" valign="middle">Epidemiol&#243;gicas</th>
                <th align="center" valign="middle">Medidas</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Idade, md (FIQ) - anos</td>
                <td align="center" valign="middle">58 (50-65)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Mulheres: md (FIQ) - anos</td>
                <td align="center" valign="middle">60 (52-68)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Homens: md (FIQ) - anos</td>
                <td align="center" valign="middle">57 (49-64)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Idosos (&#8805;60 anos), n (%)</td>
                <td align="center" valign="middle">998 (43,6)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" rowspan="2">Sexo; n (%)</td>
                <td align="center" valign="middle">Masculino: 1607 (70,2)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Feminino: 683 (29,8)</td>
              </tr>
              <tr style="background-color:#76B4CF">
                <td align="left" valign="middle">H&#225;bitos - V&#237;cios</td>
                <td align="center" valign="middle">Medidas</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Tabagismo, n (%)</td>
                <td align="center" valign="middle">1472 (64,3)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Alcoolismo, n (%)</td>
                <td align="center" valign="middle">304 (13,3)</td>
              </tr>
              <tr>
                <td style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Drogas il&#237;citas, n (%)</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">97 (4.2)</td>
              </tr>
              <tr style="background-color:#76B4CF">
                <td align="left" valign="middle">Cl&#237;nicas</td>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle">Obesidade n (%)</td>
                <td align="center" valign="middle">481 (21,0)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">IMC, Kg/m&#178;; md (FIQ)</td>
                <td align="center" valign="middle">26 (23,8-29,3)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Hipertens&#227;o arterial, n (%)</td>
                <td align="center" valign="middle">1405 (61,4)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Diabetes mellitus, n (%)</td>
                <td align="center" valign="middle">661 (28,9)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Dislipidemia, n (%)</td>
                <td align="center" valign="middle">1133 (49,5)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Hipotireoidismo, n (%)</td>
                <td align="center" valign="middle">145 (6,3)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Doen&#231;a renal cr&#244;nica, n (%)</td>
                <td align="center" valign="middle">187 (8,2)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Doen&#231;a arterial perif&#233;rica, n (%)</td>
                <td align="center" valign="middle">117 (5,1)</td>
              </tr>
              <tr>
                <td style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Acidente vascular cerebral pr&#233;vio, n (%)</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">99 (4.3)</td>
              </tr>
              <tr style="background-color:#76B4CF">
                <td align="left" valign="middle">S&#237;ndrome coronariana cr&#244;nica</td>
                <td align="center" valign="middle">Medidas</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Infarto do mioc&#225;rdio pr&#233;vio, n (%)</td>
                <td align="center" valign="middle">242 (10,6)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Angioplastia coron&#225;ria pr&#233;via, n (%)</td>
                <td align="center" valign="middle">129 (5,6)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Revasculariza&#231;&#227;o mioc&#225;rdica cir&#250;rgica pr&#233;via, n (%)</td>
                <td align="center" valign="middle">45 (2)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1">
              <p>Dados sobre hist&#243;rico m&#233;dico e comorbidades foram derivados de entrevistas com m&#233;dicos. As informa&#231;&#245;es demogr&#225;ficas e os perfis de fatores de risco foram relatados por pacientes, e uma equipe treinada analisou esses dados durante a hospitaliza&#231;&#227;o. Dados s&#227;o expressos como mediana (md) e faixa interquartil (FIQ), e vari&#225;veis categ&#243;ricas foram expressas como frequ&#234;ncia (%). Para a compara&#231;&#227;o entre sexos, o teste n&#227;o param&#233;trico de Mann-Whitney foi usado. Doen&#231;a renal cr&#244;nica (DRC) foi estimada pela equa&#231;&#227;o de Modifica&#231;&#227;o da dieta em doen&#231;a renal (MDRD) e definida quando a taxa de filtra&#231;&#227;o glomerular (TFGe) estimada &lt;60 mL/min/1,73 m2; obesidade quando IMC &#8805;30; hipertens&#227;o definida pelo uso de medicamentos anti-hipertensivos ou press&#227;o arterial sist&#243;lica &#8805;140 mmHg e/ou press&#227;o arterial diast&#243;lica &#8805;90 mmHg. Tabagismo foi definido tanto para ex-fumantes como para fumantes ativos; dislipidemia foi definida pelo uso de medicamentos espec&#237;ficos ou colesterol total &#8805;200 mg/dL, ou triglic&#233;rides &#8805;150 mg/dL; diabetes foi definida como tratamento espec&#237;fico ou hemoglobina glicada (HbA1c) &#8805;6,5%. IMC: &#205;ndice de massa corporal.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="t2">
          <label>Tabela 2</label>
          <caption>
            <title>Caracter&#237;sticas cl&#237;nicas e hemodin&#226;micas, escores de predi&#231;&#227;o e tempos pivotais foram obtidos durante a primeira consulta m&#233;dica e durante o per&#237;odo de interna&#231;&#227;o hospitalar</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="50%">
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF">
                <th align="left" valign="middle">Vari&#225;veis obtidas durante a primeira consulta</th>
                <th align="center" valign="middle">Medidas</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr>
                <td align="left" valign="middle">
                  <bold>Vari&#225;veis hemodin&#226;micas</bold>
                </td>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle">Press&#227;o arterial sist&#243;lica, mmHg; md (FIQ)</td>
                <td align="center" valign="middle">130 (115-150)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Press&#227;o arterial diast&#243;lica, mmHg; md (FIQ)</td>
                <td align="center" valign="middle">80 (70-93)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Frequ&#234;ncia card&#237;aca, md (FIQ)</td>
                <td align="center" valign="middle">76 (66-90)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" rowspan="4">Classifica&#231;&#227;o Killip-Kimball, n (%)</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; I: 1670 (72,0)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; II: 362 (15,8)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; III: 52 (2.3)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; IV: 203 (8,0)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="5"><bold>Apresenta&#231;&#227;o cl&#237;nica</bold><break/>(sintoma principal), n (%)</td>
                <td align="center" valign="middle">Dor t&#237;pica: 1939 (88,5)</td>
              </tr>
              <tr>
                <td align="center" valign="middle">Dor at&#237;pica: 166 (7,6)</td>
              </tr>
              <tr>
                <td align="center" valign="middle">Dispneia: 38 (1.7)</td>
              </tr>
              <tr>
                <td align="center" valign="middle">S&#237;ncope: 26 (1.2)</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <xref ref-type="table-fn" rid="TFN3">*</xref>
                  <italic>Alguns pacientes (4%) com mais de um sintoma relatado</italic>
                </td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">
                  <bold>Escores de risco</bold>
                </td>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">TIMI-Risk, (0-14); md (FIQ)</td>
                <td align="center" valign="middle">3 (2-5)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Escore GRACE, (0-14); md (FIQ)</td>
                <td align="center" valign="middle">135 (115-160)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">
                  <bold>Tempos pivotais</bold>
                </td>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle">Tempo dor-unidade de sa&#250;de, min; md (FIQ)</td>
                <td align="center" valign="middle">120 (60-220)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Tempo dor-agulha, min; md (FIQ)</td>
                <td align="center" valign="middle">222 (140-345)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Tempo porta-agulha, min; md (FIQ)</td>
                <td align="center" valign="middle">71 (42-135)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Tempo lise-angiografia, horas, md (FIQ)</td>
                <td align="center" valign="middle">12 (5,67-23)</td>
              </tr>
              <tr style="background-color:#76B4CF">
                <td align="left" valign="middle">
                  <bold>Vari&#225;veis obtidas durante a interna&#231;&#227;o hospitalar</bold>
                </td>
                <td align="center" valign="middle">Medidas</td>
              </tr>
              <tr>
                <td align="left" valign="middle">
                  <bold>Biomarcadores de necrose</bold>
                </td>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle">Troponina inicial, mg/L; md (FIQ)</td>
                <td align="center" valign="middle">2655 (538-7967)</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Troponina m&#225;xima, mg/L; md (FIQ)</td>
                <td align="center" valign="middle">4718 (1481-9842)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">
                  <bold>Vari&#225;veis laboratoriais</bold>
                </td>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Hemoglobina/hemat&#243;critos, g/dL/%; m &#177; DP</td>
                <td align="center" valign="middle">14,37 &#177; 2,09 /42,92 &#177; 12,56</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Glicemia do sangue/Hemoglobina glicada, mg/dL / %; md (FIQ)</td>
                <td align="center" valign="middle">122 (102-160) / 6 (5,6-6,8)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Colesterol total, mg/dL; md (FIQ)</td>
                <td align="center" valign="middle">191 (157-225)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">HDL-C, mg/dL; md (FIQ)</td>
                <td align="center" valign="middle">37 (25-46)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">LDL-C, mg/dL; md (FIQ)</td>
                <td align="center" valign="middle">110 (60-142)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Triglic&#233;rides, mg/dL; md (FIQ)</td>
                <td align="center" valign="middle">118 (77-175)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN3">*</xref>AST, u/L; md (FIQ)</td>
                <td align="center" valign="middle">144 (63-280)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN4">&#8224;</xref>ALT, u/L; md (FIQ)</td>
                <td align="center" valign="middle">43 (27-72)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Creatinina, mg/dL; md (FIQ)</td>
                <td align="center" valign="middle">0,9 (0,74-1,10)</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Taxa de filtra&#231;&#227;o glomerular estimada, (MDRD); md (FIQ)</td>
                <td align="center" valign="middle">85 (64-107)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN2">
              <p>Notas: Dados s&#227;o expressos como mediana (md) e faixa interquartil (FIQ) ou m&#233;dia e desvio padr&#227;o (m &#177; dp), e vari&#225;veis categ&#243;ricas foram expressas como frequ&#234;ncia (%). M&#233;tricas de tempo s&#227;o expressas em minutos (min). Taxa de filtra&#231;&#227;o glomerular por Modifica&#231;&#227;o da dieta em doen&#231;a renal (MDRD)</p>
            </fn>
            <fn id="TFN3">
              <label>*</label>
              <p>AST: aspartato aminotransferase</p>
            </fn>
            <fn id="TFN4">
              <label>&#8224;</label>
              <p>ALT: alanina aminotransferase.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Escores de predi&#231;&#227;o, apresenta&#231;&#227;o cl&#237;nica e tempos pivotais</title>
        <p>Na an&#225;lise dos sintomas isqu&#234;micos, a maioria dos pacientes relataram dor tor&#225;cica definida como t&#237;pica, que pode ou n&#227;o estar associada a dispneia e s&#237;ncope. Angina antes do evento estava presente em 28%, que era mais prevalente em pacientes com infarto do mioc&#225;rdio pr&#233;vio. As mulheres apresentaram uma alta frequ&#234;ncia de sintomas at&#237;picos, tais como dispneia e s&#237;ncope, conforme mostrado na <xref ref-type="table" rid="t3">Tabela 3</xref>.</p>
        <table-wrap id="t3">
          <label>Tabela 3</label>
          <caption>
            <title>Vari&#225;veis associadas ao tipo de apresenta&#231;&#227;o cl&#237;nica em um modelo univariado e ap&#243;s ajustes multivariados em regress&#227;o log&#237;stica multinomial</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="20%">
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF">
                <th align="left" valign="middle">Modelo sem ajustes</th>
                <th align="center" valign="middle">Dor t&#237;pica</th>
                <th align="center" valign="middle">Dor at&#237;pica</th>
                <th align="center" valign="middle">Dispneia</th>
                <th align="center" valign="middle">S&#237;ncope</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr>
                <td align="left" valign="middle">Vari&#225;veis</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle"/>
                <td align="center" valign="middle">n = 1939</td>
                <td align="center" valign="middle">n = 166</td>
                <td align="center" valign="middle">n = 38</td>
                <td align="center" valign="middle">n = 26</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Masculino</td>
                <td align="center" valign="middle">0,95 <break/>(0,71-1,27), p=0,74</td>
                <td align="center" valign="middle">1,05 <break/>(0,79-1,40), p=0,73</td>
                <td align="center" valign="middle"><bold>0,51</bold><break/>(0,27-0,96), p=0,026</td>
                <td align="center" valign="middle"><bold>0,39</bold><break/>(0,18-0,83), p=0,018</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Obesidade</td>
                <td align="center" valign="middle">1,07 <break/>(0,78-1,50), p=0,65</td>
                <td align="center" valign="middle">0,92 <break/>(0,67-1,28), p=0,65</td>
                <td align="center" valign="middle"><bold>0,30</bold><break/>(0,09-0,98), p=0,02</td>
                <td align="center" valign="middle">0,29 <break/>(0,07-1,26), p=0,09</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Alcoolismo</td>
                <td align="center" valign="middle">0,80 <break/>(0,56-1,15), p=0,24</td>
                <td align="center" valign="middle">1,24 <break/>(0,86-1,78), p=0,24</td>
                <td align="center" valign="middle">1,15 <break/>(0,48-2,77), p=0,44</td>
                <td align="center" valign="middle">1,49 <break/>(0,56-3,97), p=0,39</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Hipertens&#227;o</td>
                <td align="center" valign="middle">0,96 <break/>(0,73-1,26), p=0,78</td>
                <td align="center" valign="middle">1,03 <break/>(0,79-1,35), p=0,79</td>
                <td align="center" valign="middle">1,31 <break/>(0,67-2,56), p=0,26</td>
                <td align="center" valign="middle">0,67 <break/>(0,31-1,44), p =0,32</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Dislipidemia</td>
                <td align="center" valign="middle"><bold>1,39</bold><break/>(1,07-1,81), p=0,013</td>
                <td align="center" valign="middle"><bold>0,71</bold><break/>(0,55-0,93), p=0,013</td>
                <td align="center" valign="middle">1,25 <break/>(0,66-2,35), p=0,52</td>
                <td align="center" valign="middle"><bold>0,35</bold><break/>(0,15-0,84), p =0,019</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Infarto do mioc&#225;rdio pr&#233;vio</td>
                <td align="center" valign="middle">1,05 <break/>(0,68-1,61), p=0,81</td>
                <td align="center" valign="middle">0,95 <break/>(0,62-1,46), p=0,82</td>
                <td align="center" valign="middle"><bold>3,31</bold><break/>(1,63-6,72), p=0,002</td>
                <td align="center" valign="middle">0,76 <break/>(0,16-2,86), p =0,59</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Acidente vascular cerebral pr&#233;vio</td>
                <td align="center" valign="middle">0,75 <break/>(0,42-1,34), p=0,34</td>
                <td align="center" valign="middle">1,32 <break/>(0,74-2,37), p=0,34</td>
                <td align="center" valign="middle">1,82 <break/>(0,55-6,00), p=0,24</td>
                <td align="center" valign="middle">0,85 <break/>(0,11-6,32), p =0,87</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Doen&#231;a arterial perif&#233;rica</td>
                <td align="center" valign="middle">0,78 <break/>(0,45-1,35), p=0,30</td>
                <td align="center" valign="middle">1,27 <break/>(0,74-2,20), p=0,38</td>
                <td align="center" valign="middle">1,52 <break/>(0,46-5,00), p=0,45</td>
                <td align="center" valign="middle">0,71 <break/>(0,09-5,29), p =0,74</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Doen&#231;a renal cr&#244;nica</td>
                <td align="center" valign="middle"><bold>0,53</bold><break/>(0,35-0,79), p=0,002</td>
                <td align="center" valign="middle"><bold>1,88</bold><break/>(1,26-2,80), p=0,002</td>
                <td align="center" valign="middle"><bold>4,47</bold><break/>(2,19-9,10), p&lt;0,001</td>
                <td align="center" valign="middle">1,97 <break/>(0,67-5,77), p =0,27</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Tabagismo</td>
                <td align="center" valign="middle">1,17 <break/>(0,90-1,53), p=0,23</td>
                <td align="center" valign="middle">0,85 <break/>(0,65-1,11), p=0,23</td>
                <td align="center" valign="middle">1,15 <break/>(0,59-2,25), p=0,74</td>
                <td align="center" valign="middle">0,59 <break/>(0,27-1,27), p =0,22</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Diabetes</td>
                <td align="center" valign="middle">0,95 <break/>(0,72-1,27), p=0,76</td>
                <td align="center" valign="middle">1,04 <break/>(0,78-1,39), p=0,75</td>
                <td align="center" valign="middle"><bold>2,26</bold><break/>(1,21-4,24), p=0,013</td>
                <td align="center" valign="middle">0,70 <break/>(0,28-1,74), p =0,52</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Idosos</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">0,87 <break/>(0,67-1,13), p=0,32</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">1,14 <break/>(0,88-1,48), p=0,32</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">1,77 <break/>(0,94-3,33), p=0,07</td>
                <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">0,76 <break/>(0,34-1,66) p =0,56</td>
              </tr>
              <tr style="background-color:#76B4CF">
                <td align="left" valign="middle">
                  <bold>Modelo ajustado</bold>
                </td>
                <td align="center" valign="middle">
                  <bold>Dor t&#237;pica</bold>
                </td>
                <td align="center" valign="middle">
                  <bold>Dor at&#237;pica</bold>
                </td>
                <td align="center" valign="middle">
                  <bold>Dispneia</bold>
                </td>
                <td align="center" valign="middle">
                  <bold>S&#237;ncope</bold>
                </td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Vari&#225;vel</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
                <td align="center" valign="middle"><bold>Raz&#227;o de chance</bold><break/>(IC 95%), p-valor</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Homens</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle"><bold>0,51</bold><break/>(0,26-0,97), p=0,04</td>
                <td align="center" valign="middle"><bold>0,32</bold><break/>(0,15-0,70), p=0,005</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Obesidade</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">0,29 <break/>(0,08-0,95), p =0,04</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Dislipidemia</td>
                <td align="center" valign="middle"><bold>1,44</bold><break/>(1,10-1,87), p=0,007</td>
                <td align="center" valign="middle"><bold>0,69</bold><break/>(0,53-0,90), p =0,007</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle"><bold>0,36</bold><break/>(0,15-0,87), p=0,02</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Infarto do mioc&#225;rdio pr&#233;vio</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">2,68 <break/>(1,28-5,58), p=0,008</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="left" valign="middle">Doen&#231;a renal cr&#244;nica</td>
                <td align="center" valign="middle"><bold>0,50</bold><break/>(0,34-0,75), p=0,001</td>
                <td align="center" valign="middle"><bold>1,97</bold><break/>(1,32-2,94), p=0,001</td>
                <td align="center" valign="middle"><bold>3,33</bold><break/>(1,59-6,98), p=0,001</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle">Diabetes mellitus</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle"><bold>1,93</bold><break/>(1,01-3,71), p=0,04</td>
                <td align="center" valign="middle">NA</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN5">
              <p>Notas: Os dados s&#227;o expressos para (RC; IC 95%, p-valor). Na an&#225;lise multivariada, as vari&#225;veis preditoras foram analisadas simultaneamente, de forma que o efeito de cada vari&#225;vel foi ajustado para ter um efeito nas demais. Negrito indica signific&#226;ncia estat&#237;stica. Doen&#231;a renal cr&#244;nica (DRC) foi estimada pela Modifica&#231;&#227;o da dieta em doen&#231;a renal (MDRD); idosos: idade &#8805;60 anos. Negrito indica signific&#226;ncia estat&#237;stica. NA: n&#227;o aplic&#225;vel.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>As mulheres apresentaram uma demora entre a chegada do paciente na unidade de emerg&#234;ncia e o in&#237;cio do tratamento: [mulheres (2 horas e 17 minutos) vs. homens (1 hora e 58 minutos), p=0,021]. O tempo estratificado (&#8805;240 minutos) para receber o tratamento foi favor&#225;vel aos homens: [RC 0,73; IC 95% (0,55-0,98), p=0,03]. Outra constata&#231;&#227;o relevante foi o intervalo mais longo entre o aparecimento dos sintomas e a procura de tratamento m&#233;dico entre as mulheres: [mulheres: (3 horas e 14 minutos) vs. homens (2 horas e 48 minutos), p=0,008]. Mulheres diab&#233;ticas apresentaram maior tempo entre o in&#237;cio dos sintomas at&#233; a tromb&#243;lise, incluindo, nesse per&#237;odo, a chegada &#224; unidade de pronto socorro no in&#237;cio do tratamento (intervalo entre dor e tromb&#243;lise), especialmente quando comparadas aos homens n&#227;o diab&#233;ticos (<xref ref-type="fig" rid="f1">Figura 1</xref>).</p>
        <fig id="f1">
          <label>Figura 1</label>
          <caption>
            <title>M&#233;tricas de tempo relacionadas a sexo e presen&#231;a ou aus&#234;ncia de diabetes. Nota. Tempo dor-agulha expresso como m&#233;dia (minutos). * P-valor significativo ao se comparar homens n&#227;o diab&#233;ticos com mulheres diab&#233;ticas.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf01.tif"/></fig>
        <p>A maioria dos pacientes estava em uma classe funcional baixa de acordo com o escore KK: [I (73%), II (16,3%), III (2,2%), e IV (8,6%)]; perfil de baixo risco no escore de previs&#227;o TIMI-Risk: [3, FIQ (2-5)]; e escore GRACE: [136, FIQ (117-161)]. Aproximadamente 24% dos pacientes foram encaminhados para angioplastia de resgate, conforme avalia&#231;&#227;o da equipe m&#233;dica local, por n&#227;o atingirem os crit&#233;rios para uma terapia de reperfus&#227;o bem-sucedida.</p>
      </sec>
      <sec>
        <title>Achados angiogr&#225;ficos (art&#233;ria culpada)</title>
        <p>1) art&#233;ria descendente anterior esquerda (ADAE): 46,3%; 2) art&#233;ria coron&#225;ria direita (ACD): 32,1%; 3) art&#233;ria circunflexa esquerda (ACX): 6,1%; 4) art&#233;ria coron&#225;ria esquerda principal (ACEP): 0,4%; 5) art&#233;ria descendente posterior (ADP): 0,3%; 6) tronco ventricular posterior (VP): 0,9%; 7) ramifica&#231;&#227;o marginal esquerda: 1,0%; 8) ramifica&#231;&#227;o diagonal: 0,7%; 9) art&#233;ria n&#227;o identificada: 12,1% A an&#225;lise de subgrupo n&#227;o encontrou associa&#231;&#245;es significativas entre a art&#233;ria culpada e fatores de risco pr&#233;vios, nem com a apresenta&#231;&#227;o cl&#237;nica inicial de sintomas isqu&#234;micos.</p>
        <p>Os escores TIMI-flow e MBG (iniciais e finais) foram registrados, classificados de 0 a 3: [TIMI-flow inicial: (3)] e [MBG inicial: (3)] em aproximadamente 60% e 42%, respectivamente. Quando esses escores p&#243;s-procedimento percut&#226;neos foram analisados, os &#237;ndices de TIMI-flow final: (3) e de MGB final: (3) eram 78% e 58%, respectivamente, com um alto n&#237;vel de confiabilidade. O <bold>&#945;</bold> de Crombach = 0,88.</p>
      </sec>
      <sec>
        <title>Desfechos associados a complica&#231;&#245;es no laborat&#243;rio de hemodin&#226;mica e pelo evento &#237;ndice</title>
        <p>A dura&#231;&#227;o m&#233;dia da interna&#231;&#227;o hospitalar foi de 2,0 &#177; 1,3 dias, da admiss&#227;o no hospital terci&#225;rio at&#233; a alta ou transfer&#234;ncia para um hospital de contrarrefer&#234;ncia para continuar o tratamento. Um per&#237;odo de interna&#231;&#227;o mais longo foi observado no grupo dos idosos: [1,9 dias (n&#227;o idosos) vs. 2,3 dias (idosos), p=0,004] e notadamente no grupo de pacientes que precisaram receber transfus&#245;es de material sangu&#237;neo devido a sangramento: [1,9 dias (sem sangramento) vs. 3,4 dias (sangramento importante), p=0,004].</p>
        <p>O presente estudo registrou a frequ&#234;ncia das complica&#231;&#245;es durante o procedimento angiogr&#225;fico, bem como aqueles observados durante o per&#237;odo de hospitaliza&#231;&#227;o. Essas complica&#231;&#245;es inclu&#237;ram eventos importantes, tais como dissec&#231;&#227;o ou ruptura da coron&#225;ria, entre outros, como complica&#231;&#245;es cl&#237;nicas, arritmias e sangramento no local na incis&#227;o. Embora infrequentes, sangramentos importantes eram independentemente associados &#224; mortalidade hospitalar. &#205;ndices de sangramento mais altos foram observados no grupo dos idosos: [RC: 1,86; IC 95% (1,04-3,16), p=0,023].</p>
      </sec>
      <sec>
        <title>Preditores e vari&#225;veis associadas &#224;s taxas de mortalidade</title>
        <p>A taxa de mortalidade hospitalar era 5,6%, com 128 mortes, das quais 23 (17,9%) ocorreram no laborat&#243;rio de hemodin&#226;mica, com instabilidade el&#233;trica ou complica&#231;&#245;es mec&#226;nicas sendo as causas mais prevalentes, e com uma incid&#234;ncia mais alta ocorrendo no grupo de resgate (11,5% vs. 2,4%). Em rela&#231;&#227;o &#224;s caracter&#237;sticas epidemiol&#243;gicas e fatores de risco, uma distribui&#231;&#227;o similar das vari&#225;veis analisadas foi observada em pacientes sobreviventes, em compara&#231;&#227;o com o que morreram durante o per&#237;odo de interna&#231;&#227;o, exceto pelo escore GRACE, que apresentou valores mais altos nos pacientes que morreram [134 (115-157) vs. 202 (155-233), p&lt;0,001]. O escore GRACE (escore mediano 136) apresentou boa sensibilidade mais especificidade baixa [sensibilidade: 0,86%; especificidade: 0,53%]. O escore de previs&#227;o TIMI-Risk (escore mediano 3) apresentou os seguintes resultados: sensibilidade: 0,87%; especificidade: 0,57% (<xref ref-type="table" rid="t4">Tabela 4</xref>).</p>
        <table-wrap id="t4">
          <label>Tabela 4</label>
          <caption>
            <title>Vari&#225;veis cl&#237;nicas e epidemiol&#243;gicas entre os grupos de &#8220;sobreviventes&#8221; e &#8220;mortes&#8221;</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="25%">
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
              <tr style="background-color:#76B4CF">
                <th align="left" valign="middle" colspan="2"/>
                <th align="center" valign="middle">Grupo de sobreviventes</th>
                <th align="center" valign="middle">Grupo de mortes</th>
                <th align="center" valign="middle">p-valor</th>
              </tr>
            </thead>
            <tbody style="border-bottom: thin solid; border-color: #000000">
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Vari&#225;veis</bold>
                </td>
                <td align="center" valign="middle">2162 (94,4%)</td>
                <td align="center" valign="middle">128 (5,6%)</td>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">
                  <bold>Epidemiol&#243;gicas</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">Idade, anos:</td>
                <td align="center" valign="middle">58 (50-66)</td>
                <td align="center" valign="middle">56 (48-65)</td>
                <td align="center" valign="middle">
                  <bold>0,047</bold>
                </td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Sexo masculino:</td>
                <td align="center" valign="middle">Homens: 71,1%</td>
                <td align="center" valign="middle">Homens: 53,2%</td>
                <td align="center" valign="middle">
                  <bold>0,02</bold>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Escores de risco</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2" rowspan="4">Killip-Kimball, (%)</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; I: 75,6%</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; I: 20,6%</td>
                <td align="center" valign="middle">0,09</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; II: 16,4%</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; II: 7,9%</td>
                <td align="center" valign="middle">0,42</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; III: 2,2%</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; III: 4,8%</td>
                <td align="center" valign="middle">0,96</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Killip-Kimball &#8211; IV: 5,7%</td>
                <td align="center" valign="middle">Killip-Kimball &#8211; IV: 66,5%</td>
                <td align="center" valign="middle">0,08</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">TIMI-Risk:</td>
                <td align="center" valign="middle">3 (2-5)</td>
                <td align="center" valign="middle">6 (5-8,2)</td>
                <td align="center" valign="middle">0,26</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Escore GRACE:</td>
                <td align="center" valign="middle">134 (115-157)</td>
                <td align="center" valign="middle">202 (155-233)</td>
                <td align="center" valign="middle">
                  <bold>p &lt;0,001</bold>
                </td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Vari&#225;veis de ECG</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" rowspan="3"/>
                <td align="left" valign="middle" rowspan="3">Parede do ECG</td>
                <td align="center" valign="middle">parede anterior</td>
                <td align="center" valign="middle">parede anterior</td>
                <td align="center" valign="middle">0,68</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">parede inferior</td>
                <td align="center" valign="middle">parede inferior</td>
                <td align="center" valign="middle">0,58</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">parede lateral</td>
                <td align="center" valign="middle">parede lateral</td>
                <td align="center" valign="middle">0,45</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Vari&#225;veis hemodin&#226;micas</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2" rowspan="4">Art&#233;ria relacionada ao infarto</td>
                <td align="center" valign="middle">ADA: 45,5%</td>
                <td align="center" valign="middle">ADA: 38,9%</td>
                <td align="center" valign="middle" rowspan="4">0,84</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">ACD: 32,5%</td>
                <td align="center" valign="middle">ACD: 36,5%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">ACX: 6%</td>
                <td align="center" valign="middle">ACX: 10,3%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Outros: 22,4%</td>
                <td align="center" valign="middle">Outros: 14,3%</td>
              </tr>
              <tr>
                <td colspan="2" align="left" valign="middle"><xref ref-type="table-fn" rid="TFN7">&#8224;</xref>Fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE):</td>
                <td align="center" valign="middle">50 (40-59)</td>
                <td align="center" valign="middle">49 (40-60)</td>
                <td align="center" valign="middle">0,17</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2" rowspan="4">TIMI-flow inicial</td>
                <td align="center" valign="middle">TIMI-0: 19,6%</td>
                <td align="center" valign="middle">TIMI-0: 36,8%</td>
                <td align="center" valign="middle" rowspan="4">0,97</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">TIMI-1: 3,3%</td>
                <td align="center" valign="middle">TIMI-1: 11,3%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">TIMI-2: 15,4%</td>
                <td align="center" valign="middle">TIMI-2: 17%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">TIMI-3: 61,7%</td>
                <td align="center" valign="middle">TIMI-3: 34,9%</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2" rowspan="4">TIMI-flow final</td>
                <td align="center" valign="middle">TIMI-0: 4,6%</td>
                <td align="center" valign="middle">TIMI-0: 19,8%</td>
                <td align="center" valign="middle" rowspan="4">0,10</td>
              </tr>
              <tr>
                <td align="center" valign="middle">TIMI-1: 1,2%</td>
                <td align="center" valign="middle">TIMI-1: 4,7%</td>
              </tr>
              <tr>
                <td align="center" valign="middle">TIMI-2: 14,1%</td>
                <td align="center" valign="middle">TIMI-2: 24,5%</td>
              </tr>
              <tr>
                <td align="center" valign="middle">TIMI-3: 80,1%</td>
                <td align="center" valign="middle">TIMI-3: 50,9%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2" rowspan="4">Grau Blush mioc&#225;rdico inicial:</td>
                <td align="center" valign="middle">Blush-0: 40,8%</td>
                <td align="center" valign="middle">Blush-0: 71,7%</td>
                <td align="center" valign="middle" rowspan="4">0,77</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Blush-1: 3,8%</td>
                <td align="center" valign="middle">Blush-1: 2,8%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Blush-2: 2,6%</td>
                <td align="center" valign="middle">Blush-2: 1,9%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="center" valign="middle">Blush-3: 52,8%</td>
                <td align="center" valign="middle">Blush-3: 23,6%</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2" rowspan="4">Grau Blush mioc&#225;rdico final:</td>
                <td align="center" valign="middle">Blush-0: 24,7%</td>
                <td align="center" valign="middle">Blush-0: 61%</td>
                <td align="center" valign="middle" rowspan="4">0,39</td>
              </tr>
              <tr>
                <td align="center" valign="middle">Blush-1: 8,8%</td>
                <td align="center" valign="middle">Blush-1: 9,5%</td>
              </tr>
              <tr>
                <td align="center" valign="middle">Blush-2: 6,1%</td>
                <td align="center" valign="middle">Blush-2: 5,7%</td>
              </tr>
              <tr>
                <td align="center" valign="middle">Blush-3: 60,4%</td>
                <td align="center" valign="middle">Blush-3: 23,8%</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">
                  <bold>Vari&#225;veis laboratoriais</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Troponina inicial (na linha de base)</td>
                <td align="center" valign="middle">2704 (618-7889)</td>
                <td align="center" valign="middle">3413 (280-11506)</td>
                <td align="center" valign="middle">0,83</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Troponina m&#225;xima:</td>
                <td align="center" valign="middle">4820 (1661-9796)</td>
                <td align="center" valign="middle">7925 (1145-1774)</td>
                <td align="center" valign="middle">0,80</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2"><sup>*</sup>TFGe, (MDRD):</td>
                <td align="center" valign="middle">86 (67-107)</td>
                <td align="center" valign="middle">91 (66-111)</td>
                <td align="center" valign="middle">0,62</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Hemoglobina:</td>
                <td align="center" valign="middle">14,5 (13,3-15,7)</td>
                <td align="center" valign="middle">13,7 (12,5-15,1)</td>
                <td align="center" valign="middle">0,05</td>
              </tr>
              <tr style="background-color:#C7DFEC">
                <td align="left" valign="middle" colspan="2">Hemat&#243;critos:</td>
                <td align="center" valign="middle">42,9 (39,6-46,2)</td>
                <td align="center" valign="middle">41 (37,9-45,5)</td>
                <td align="center" valign="middle">0,14</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">
                  <bold>Tempos pivotais</bold>
                </td>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
                <td align="center" valign="middle"/>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">Tempo dor-agulha, (min):</td>
                <td align="center" valign="middle">220 (140-345)</td>
                <td align="center" valign="middle">245 (150-516)</td>
                <td align="center" valign="middle">0,08</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2">Tempo porta-agulha, (min):</td>
                <td align="center" valign="middle">75 (45-135)</td>
                <td align="center" valign="middle">78,5 (45-163,7)</td>
                <td align="center" valign="middle">0,12</td>
              </tr>
              <tr>
                <td align="left" valign="middle" colspan="2"><xref ref-type="table-fn" rid="TFN8">&#8225;</xref>Tempo lise-cateterismo, (horas):</td>
                <td align="center" valign="middle">11 (5-22)</td>
                <td align="center" valign="middle">11 (5-21,7)</td>
                <td align="center" valign="middle">0,43</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN6">
              <p>Notas: Dados s&#227;o expressos como mediana (md) e faixa interquartil (FIQ), e vari&#225;veis categ&#243;ricas foram expressas como frequ&#234;ncia (%). O teste &#967;&#178; (qui-quadrado) foi usado para as amostras independentes. TFGe: Taxa de filtra&#231;&#227;o glomerular estimada por Modifica&#231;&#227;o da dieta em doen&#231;a renal (MDRD).</p>
            </fn>
            <fn id="TFN7">
              <label>&#8224;</label>
              <p>FEVE: Fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda.</p>
            </fn>
            <fn id="TFN8">
              <label>&#8225;</label>
              <p>Lise-CATE (fibrin&#243;lise-cateterismo); ECG: eletrocardiograma. Negrito indica signific&#226;ncia estat&#237;stica.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>A classifica&#231;&#227;o funcional KK demonstrou bom desempenho na previs&#227;o da mortalidade hospitalar: AUC: [0,77 IC 95% (0,73-0,81), p&lt;0,001] no grupo com um escore &#8805;II, demonstrando melhor precis&#227;o que os escores angiogr&#225;ficos de reperfus&#227;o: TIMI-Flow (3) e MBG (3), AUC: [0,69; IC 95% (0,64-0,75), p&lt;0,001], bem como um melhor desempenho quando os pacientes foram estratificados de acordo com a fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda, AUC: [0.52; 95% CI (0,47-0,58), p=0,34].</p>
        <p>Nosso estudo teve o cuidado de avaliar o desempenho dos escores de previs&#227;o: TIMI-Risk, AUC: [0,79; IC 95% (0,75-0,84)], p&lt;0,001; GRACE, AUC: [0,82; IC 95% (0,78-0,86), p&lt;0,001]; AUC de Killip-Kimball AUC: [0,82; IC 95% (0,78-0,87), p&lt;0,001], (<xref ref-type="fig" rid="f2">Figura 2</xref>). Para as categorias de Killip-Kimball, os seguintes escores foram obtidos: raz&#227;o de probabilidade positiva: 3,76; raz&#227;o de probabilidade negativa: 0,33; e RCD (Raz&#227;o de chance diagn&#243;stica: 11,39 para os &#237;ndices de previs&#227;o de mortalidade hospitalar, definidos como a probabilidade dos pacientes na classe funcional &#8805; II (II, III, IV) que morreram, em rela&#231;&#227;o &#224; probabilidade dos pacientes do grupo funcional &#8805; II que sobreviveram.</p>
        <fig id="f2">
          <label>Figura 2</label>
          <caption>
            <title>Escores de previs&#227;o para mortalidade hospitalar. Nota. Estat&#237;sticas C, ROC e AUC. TIMI-Risk, AUC: [0,79; IC 95% (0,75-0,84), p&lt;0,001]; Escore GRACE, AUC: [0,82; IC 95% (0,78-0,86), p&lt;0,001]; Killip-Kimball, AUC: [0,82; IC 95% (0,78-0,87), p&lt;0,001].</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf02.tif"/></fig>
        <p>Em um modelo de regress&#227;o log&#237;stica com an&#225;lises de covari&#226;ncia, obesidade, sexo feminino, pacientes com diabetes mellitus, insufici&#234;ncia renal cr&#244;nica, acidente vascular cerebral pr&#233;vio e a idade estavam associados aos &#237;ndices mais altos de eventos fatais (<xref ref-type="fig" rid="f3">Figura 3</xref>). O ajuste do modelo apresentou um bom desempenho preditivo.</p>
        <fig id="f3">
          <label>Figura 3</label>
          <caption>
            <title>Preditores de mortalidade hospitalar Nota. Vari&#225;veis de previs&#227;o em um modelo de regress&#227;o log&#237;stica bin&#225;ria, com RC-IC 95%, e p-valor.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf03.tif"/></fig>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>Mesmo com a exist&#234;ncia de v&#225;rias terapias eficazes, as informa&#231;&#245;es qualitativas ainda n&#227;o est&#227;o dispon&#237;veis para estratifica&#231;&#227;o, especialmente na estrat&#233;gia f&#225;rmaco-invasiva, em que a avalia&#231;&#227;o de sa&#250;de inicial parece estar proximamente relacionada ao progn&#243;stico. H&#225; muitas abordagens para a estratifica&#231;&#227;o de risco. Algumas s&#227;o muito complexas e caras, mas procedimentos simples tamb&#233;m podem ser eficazes. Sob essa perspectiva, o presente estudo tentou oferecer dados epidemiol&#243;gicos sobre as v&#225;rias formas de sintomas isqu&#234;micos agudos, bem como demonstrar a aplicabilidade de alguns escores de previs&#227;o em pacientes que receberam cuidados m&#233;dicos principalmente nas unidades de sa&#250;de b&#225;sica, e foram encaminhados a um hospital universit&#225;rio terci&#225;rio para estudos angiogr&#225;ficos e procedimentos invasivos.</p>
      <p>Nem todas as s&#237;ndromes coron&#225;rias agudas apresentam sinais ou sintomas cl&#225;ssicos, tais como dor pr&#233;-cordial ou retroesternal t&#237;pica, o que atrasa o diagn&#243;stico e as abordagens terap&#234;uticas e afeta o progn&#243;stico. Portanto, h&#225; grande interesse nos principais determinantes de mortalidade e complica&#231;&#245;es de curto prazo ap&#243;s um infarto agudo do mioc&#225;rdio.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> Nos &#250;ltimos anos, grandes avan&#231;os no diagn&#243;stico e no tratamento contribu&#237;ram para a redu&#231;&#227;o da mortalidade devido a doen&#231;a card&#237;aca coron&#225;ria. Na verdade, foram feitos esfor&#231;os para se alcan&#231;ar a preven&#231;&#227;o prim&#225;ria mais ativa, com um controle melhor dos fatores de risco, e recursos farmacol&#243;gicos. Entretanto, a preven&#231;&#227;o e o tratamento de doen&#231;as cardiovasculares precisam estar amplamente dispon&#237;veis e aplicados sem distin&#231;&#227;o.</p>
      <sec>
        <title>Apresenta&#231;&#227;o cl&#237;nica e eventos em subgrupos</title>
        <p>H&#225; evid&#234;ncias de diferen&#231;as entre os sexos na aplica&#231;&#227;o dos avan&#231;os tecnol&#243;gicos.<sup><xref ref-type="bibr" rid="B12">12</xref>&#8211;<xref ref-type="bibr" rid="B15">15</xref></sup> Em nossa an&#225;lise, os sintomas referidos como dispneia e epis&#243;dios sincopais foram significativamente mais prevalentes em mulheres, e eram particularmente relevantes para esse grupo, apresentando taxas de mortalidade mais altas. V&#225;rios mecanismos multifatoriais foram propostos para a maior mortalidade card&#237;aca entre mulheres. As explica&#231;&#245;es geralmente incluem um di&#226;metro menor da coron&#225;ria em mulheres, fluxo colateral baixo, predisposi&#231;&#227;o a eros&#227;o de placas e emboliza&#231;&#227;o distal, e outras caracter&#237;sticas fenot&#237;picas de placas ateroscler&#243;ticas.<sup><xref ref-type="bibr" rid="B16">16</xref>&#8211;<xref ref-type="bibr" rid="B18">18</xref></sup> As mulheres geralmente apresentam eventos aproximadamente uma d&#233;cada depois dos homens, especialmente na p&#243;s-menopausa, possivelmente devido &#224; diminui&#231;&#227;o do estrog&#234;nio e &#224; perda de efeitos protetivos, com a consequente piora dos fatores de risco, ganho de peso, e resist&#234;ncia &#224; insulina.<sup><xref ref-type="bibr" rid="B19">19</xref>&#8211;<xref ref-type="bibr" rid="B21">21</xref></sup> Em nossa coorte, a demora em reconhecer os sintomas, possivelmente devido a sua apar&#234;ncia at&#237;pica, teve um impacto em m&#233;tricas temporais para tromb&#243;lise, tais como os registrados nos grupos de mulheres e diab&#233;ticos.</p>
        <p>Diabetes &#233; um fator de risco potencial em mulheres. Uma meta-an&#225;lise para estimar o risco relativo de doen&#231;a card&#237;aca coron&#225;ria fatal associada ao diabetes, envolvendo aproximadamente 450.000 pacientes, revelou um risco relativo 50% mais alto nas mulheres.<sup><xref ref-type="bibr" rid="B22">22</xref></sup> O risco coron&#225;rio mais alto associado ao diabetes em mulheres pode refletir um vi&#233;s de tratamento favor&#225;vel aos homens. Estudos mostram que homens com diabetes ou doen&#231;a cardiovascular estabelecida t&#234;m maior probabilidade de receber tratamento com antiagregantes plaquet&#225;rios, estatinas ou medicamentos anti-hipertensivos que as mulheres.<sup><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup> Al&#233;m disso, h&#225; relat&#243;rios de m&#225; ades&#227;o &#224;s recomenda&#231;&#245;es de diretrizes entre as mulheres, tais como um tempo mais longo entre a chegada no hospital e a coloca&#231;&#227;o do bal&#227;o.<sup><xref ref-type="bibr" rid="B25">25</xref>&#8211;<xref ref-type="bibr" rid="B28">28</xref></sup> Tamb&#233;m observou-se que os homens receberam a terapia fibrinol&#237;tica mais cedo, possivelmente devido &#224; apresenta&#231;&#227;o mais clara de sintomas isqu&#234;micos.</p>
        <p>A apar&#234;ncia cl&#237;nica, definida acima como dispneia, era mais prevalente em pacientes com infartos anteriores, possivelmente devido a comprometimento mioc&#225;rdico adicional. O relato de dispneia tamb&#233;m foi feito por pacientes com diabetes. Isso pode ter tido um impacto significativo na taxa de mortalidade devido &#224; aus&#234;ncia de sintomas t&#237;picos ou sinais de alerta.</p>
      </sec>
      <sec>
        <title>Escores de risco</title>
        <p>Embora n&#227;o exista um modelo de estratifica&#231;&#227;o ideal, ele deve conter as seguintes caracter&#237;sticas: facilidade de implementa&#231;&#227;o, objetividade, precis&#227;o e uso disseminado. Killip-Kimball, um m&#233;todo de classifica&#231;&#227;o funcional aplicado durante a primeira consulta m&#233;dica, foi um preditor importante de desfechos fatais durante o per&#237;odo de interna&#231;&#227;o hospitalar, com um bom valor preditivo negativo. O &#237;ndice de gravidade da insufici&#234;ncia card&#237;aca em pacientes com infarto agudo do mioc&#225;rdio foi proposto por Thomas Killip e John Kimball numa tentativa de medir o risco de eventos hospitalares e poss&#237;vel benef&#237;cio da gest&#227;o espec&#237;fica do tratamento m&#233;dico oferecido em unidades de tratamento coron&#225;rio. Nossa an&#225;lise destaca o uso cl&#237;nico de um exame f&#237;sico como uma ferramenta simples, sem requisitos tecnol&#243;gicos sofisticados para identificar os sinais de insufici&#234;ncia card&#237;aca na admiss&#227;o hospitalar, que desempenhou um papel progn&#243;stico relevante nas taxas de mortalidade durante a interna&#231;&#227;o, uma vez que as propor&#231;&#245;es de mortes e na distribui&#231;&#227;o de dados de sobrevida foram significativamente diferentes dentro da classe &gt;I de Killip-Kimball.</p>
      </sec>
      <sec>
        <title>Taxas de mortalidade hospitalar</title>
        <p>A taxa de mortalidade, incluindo eventos durante o procedimento angiogr&#225;fico e os relacionados ao evento &#237;ndice, estava associada a complica&#231;&#245;es mec&#226;nicas e dist&#250;rbios el&#233;tricos graves e irrevers&#237;veis. Relatou-se que a demora no tempo de recanaliza&#231;&#227;o est&#225; associada a um comprometimento maior da fun&#231;&#227;o ventricular, dist&#250;rbios de microcircula&#231;&#227;o e taxas de mortalidade mais altas.<sup><xref ref-type="bibr" rid="B29">29</xref></sup> &#201; interessante notar que nosso estudo n&#227;o identificou associa&#231;&#227;o entre as taxas de mortalidade entre pacientes no grupo com fra&#231;&#227;o de eje&#231;&#227;o ventricular esquerda (FEVE) mais baixa nem com os escores angiogr&#225;ficos. De fato, a les&#227;o culpada totalmente oclu&#237;da (TIMI-flow-0) n&#227;o demonstrou estar associada &#224;s maiores taxas de mortalidade hospitalar ap&#243;s o IAMCSST tratado com TNK, em compara&#231;&#227;o com aqueles que apresentavam TIMI-flow &#8805;1. Al&#233;m disso, as arritmias ventriculares malignas podem aparecer mais cedo nos processos isqu&#234;micos e continuar a ser uma causa esperada de morte em infartos do mioc&#225;rdio.<sup><xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup> Em nossa coorte, as taxas de mortalidade hospitalar foram mais altas entre os pacientes que apresentaram arritmias ventriculares malignas do que os pacientes que n&#227;o apresentaram arritmias ventriculares, definidas como taquicardia ou fibrila&#231;&#227;o. Entretanto, devido &#224; caracter&#237;stica observacional de nosso estudo, v&#225;rias dificuldades foram encontradas na caracteriza&#231;&#227;o das arritmias ventriculares, especialmente no per&#237;odo p&#243;s-angioplastia, j&#225; que a ocorr&#234;ncia desses eventos foi era dif&#237;cil de prever. Portanto, pode-se especular que dist&#250;rbios el&#233;tricos graves podem ser um marcador forte de desfechos hospitalares, apesar do sucesso da interven&#231;&#227;o coron&#225;ria percut&#226;nea e seus respectivos escores angiogr&#225;ficos, e tamb&#233;m podem n&#227;o estar correlacionados a FEVE. Presume-se que esse seja um marcador melhor quando aplicado a desfechos medidos no m&#233;dio e no longo prazo.</p>
        <p>Alguns subgrupos de interesse especial foram examinados em sua associa&#231;&#227;o com taxas de mortalidade, tais como o grupo das mulheres, os pacientes obesos, os diab&#233;ticos e os idosos. Nesse sentido, ap&#243;s o infarto do mioc&#225;rdio, as mulheres parecem estar em maior risco de um novo infarto e morte, o que pode ser parcialmente explicado pela idade mais avan&#231;ada, como observado em nosso estudo.</p>
        <p>Em contraste, a doen&#231;a renal cr&#244;nica (DRC) representa um fator de risco independente para o desenvolvimento de doen&#231;a card&#237;aca isqu&#234;mica, aumentando a mortalidade com o avan&#231;o do comprometimento renal. Les&#245;es renais pr&#233;vias ou resultantes do infarto est&#227;o associadas a desfechos piores.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref></sup> &#201; prov&#225;vel que haja uma rela&#231;&#227;o rec&#237;proca entre o processo ateroscler&#243;tico coron&#225;rio e a fun&#231;&#227;o renal, e a presen&#231;a de doen&#231;a coron&#225;ria esteja associada a uma piora da fun&#231;&#227;o renal. DRC e doen&#231;a cardiovascular est&#227;o intimamente relacionadas, e a presen&#231;a de uma condi&#231;&#227;o sinergicamente afeta o progn&#243;stico da outra.<sup><xref ref-type="bibr" rid="B34">34</xref></sup> Nossos dados expressam as taxas de mortalidade mais altas para esses pacientes.</p>
        <p>Pacientes que sofreram um acidente vascular cerebral pr&#233;vio tamb&#233;m apresentaram taxas mais altas de eventos fatais, destacando a necessidade de preven&#231;&#227;o e tratamento adequado para esse subgrupo.<sup><xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref></sup> O mesmo conceito pode ser aplic&#225;vel aos idosos, possivelmente devido a maior fragilidade biol&#243;gica nesse grupo. Os mecanismos para essa rela&#231;&#227;o parecem ser m&#250;ltiplos, envolvendo caracter&#237;sticas anat&#244;micas, bioqu&#237;micas e imunol&#243;gicas, ou mesmo a exposi&#231;&#227;o mais longa a fatores de risco cl&#225;ssicos. Outro achado em nossa coorte foi a taxa de mortalidade mais alta nos pacientes com diabetes mellitus, o que est&#225; de acordo com estudos pr&#233;vios.<sup><xref ref-type="bibr" rid="B37">37</xref>&#8211;39</sup> O diabetes mellitus frequentemente est&#225; associado a m&#250;ltiplos mecanismos de doen&#231;a cardiovascular, tais como obesidade, hipertens&#227;o, insufici&#234;ncia renal, inflama&#231;&#227;o subcl&#237;nica, disfun&#231;&#227;o endotelial e comprometimento microvascular. No entanto, n&#227;o foram encontradas diferen&#231;as significativas nos escores angiogr&#225;ficos de reperfus&#227;o MBG ou TIMI-flow na compara&#231;&#227;o de grupos de pacientes com e sem diabetes.</p>
      </sec>
      <sec>
        <title>Pontos fortes e limita&#231;&#245;es</title>
        <p>O presente estudo tem limita&#231;&#245;es. Primeiramente, foi um estudo observacional, com corre&#231;&#227;o de fatores de confus&#227;o medidos ou conhecidos. Portanto, n&#227;o podemos concluir que as associa&#231;&#245;es observadas s&#227;o causais. Al&#233;m disso, nossos registros incluem apenas pacientes que foram submetidos a interven&#231;&#227;o f&#225;rmaco-invasiva, desconsiderando aqueles que foram encaminhados para tratamento percut&#226;neo prim&#225;rio ou que tinham contraindica&#231;&#245;es formais para fibrin&#243;lise. Considerando que o estudo foi realizado em um &#250;nico centro universit&#225;rio, esses padr&#245;es de pr&#225;tica e resultados devem ser interpretados com cuidado. Outra limita&#231;&#227;o de nosso estudo foi a an&#225;lise dos desfechos apenas para o per&#237;odo de interna&#231;&#227;o hospitalar. Em um sentido importante, nossa valida&#231;&#227;o interna indicou que o ajuste do modelo era bom e os modelos de previs&#227;o diagn&#243;stica tiveram um bom desempenho para fazer a previs&#227;o do progn&#243;stico independentemente.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#245;es</title>
      <p>Nossos dados revelaram taxas de mortalidade hospitalar mais altas em mulheres, em pacientes com diabetes mellitus, obesidade, DRC e acidentes vasculares pr&#233;vios, bem como em idosos. A disparidade relacionada a sexo persiste nas mulheres, com demoras no reconhecimento dos sintomas de isquemia, e o in&#237;cio imediato de terapia fibrinol&#237;tica, levando a priores resultados cl&#237;nicos. A aplicabilidade do escore de Killip-Kimball para prever eventos fatais com precis&#227;o deve ser destacada, independentemente da apresenta&#231;&#227;o cl&#237;nica do evento isqu&#234;mico agudo, medido na primeira consulta m&#233;dica, especialmente na estrat&#233;gia f&#225;rmaco-invasiva.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by" id="fn1">
        <p>
          <bold>Fontes de financiamento</bold>
        </p>
        <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
      </fn>
      <fn fn-type="other" id="fn2">
        <p>
          <bold>Vincula&#231;&#227;o acad&#234;mica</bold>
        </p>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other" id="fn3">
        <p>
          <bold>Aprova&#231;&#227;o &#233;tica e consentimento informado</bold>
        </p>
        <p>Este estudo foi aprovado pelo Comit&#234; de &#201;tica da Universidade Federal de S&#227;o Paulo sob o n&#250;mero de protocolo CAAE: 38692514.1.1001.5505. Todos os procedimentos envolvidos nesse estudo est&#227;o de acordo com a Declara&#231;&#227;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#237;dos no estudo.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montecucco</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carbone</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schindler</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of ST-segment elevation myocardial infarction: Novel mechanisms and treatments</article-title>
          <source>Eur Heart J</source>
          <year>2016</year>
          <volume>37</volume>
          <issue>16</issue>
          <fpage>1268</fpage>
          <lpage>1283</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehv592</pub-id>
        </element-citation>
        <mixed-citation>1 Montecucco F, Carbone F, Schindler TH. Pathophysiology of ST-segment elevation myocardial infarction: Novel mechanisms and treatments. Eur Heart J. 2016;37(16): 1268-83. doi: 10.1093/eurheartj/ehv592.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Gershlick</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wilcox</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Danays</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yves Lambert</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>STREAM Investigative Team Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <issue>15</issue>
          <fpage>1379</fpage>
          <lpage>1387</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1301092</pub-id>
        </element-citation>
        <mixed-citation>2 Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Yves Lambert Y, et al, for the STREAM Investigative Team Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013;368(15):1379-87. doi: 10.1056/NEJMoa1301092.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piackova</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>J&#228;ger</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Farhan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Christ</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Weidinger</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
            <collab>Vienna STEMI Registry Group</collab>
          </person-group>
          <article-title>Gender differences in short- and long-term mortality in the Vienna STEMI registry</article-title>
          <source>Int J Cardiol</source>
          <year>2017</year>
          <volume>244</volume>
          <fpage>303</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.05.068</pub-id>
        </element-citation>
        <mixed-citation>3 Piackova E, J&#228;ger B, Farhan S, Christ G, Schreiber W, Weidinger F, et al. Vienna STEMI Registry Group. Gender differences in short- and long-term mortality in the Vienna STEMI registry. Int J Cardiol. 2017;244:303-8. doi: 10.1016/j.ijcard.2017.05.068.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kereiakes</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gibler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aufderheide</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the prehospital study group and the Cincinnati Heart Project</article-title>
          <source>Am Heart J</source>
          <year>1990</year>
          <volume>120</volume>
          <issue>4</issue>
          <fpage>773</fpage>
          <lpage>780</lpage>
          <pub-id pub-id-type="doi">10.1016/0002-8703(90)90192-z</pub-id>
        </element-citation>
        <mixed-citation>4 Kereiakes DJ, Weaver WD, Anderson JL, Feldman T, Gibler B, Aufderheide T, et al. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the prehospital study group and the Cincinnati Heart Project. Am Heart J. 1990;120(4):773-80. doi: 10.1016/0002-8703(90)90192-z.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibanez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Agewall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bucciarelli-Ducci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bueno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Caforio</surname>
              <given-names>ALP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2017 ESC Scientific Document Group, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)</article-title>
          <source>Eur Heart J</source>
          <year>2017</year>
          <volume>39</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id>
        </element-citation>
        <mixed-citation>5 Ibanez B, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, et al. 2017 ESC Scientific Document Group, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119-77. doi: 10.1093/eurheartj/ehx393.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Killip</surname>
              <given-names>T</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Kimball</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Treatment of myocardial infarction in a coronary care unit. a two years experience with 250 patients</article-title>
          <source>Am J Cardiol</source>
          <year>1967</year>
          <volume>20</volume>
          <issue>4</issue>
          <fpage>457</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1016/0002-9149(67)90023-9</pub-id>
        </element-citation>
        <mixed-citation>6 Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. a two years experience with 250 patients. Am J Cardiol. 1967;20(4):457-64. doi: 10.1016/0002-9149(67)90023-9.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Antman</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Charlesworth</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cairns</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation</article-title>
          <source>Circulation</source>
          <year>2000</year>
          <volume>102</volume>
          <issue>17</issue>
          <fpage>2031</fpage>
          <lpage>2037</lpage>
          <pub-id pub-id-type="doi">10.1161/01.cir.102.17.2031</pub-id>
        </element-citation>
        <mixed-citation>7 Morrow DA, Elliott M, Antman AC, Charlesworth A, Cairns R, Murphy SA, et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. Circulation. 2000;102(17):2031-7. doi: 10.1161/01.cir.102.17.2031.</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Granger</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Dabbous</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Karen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pieper</surname>
              <given-names>KS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global Registry of Acute Coronary Events Investigators Predictors of hospital mortality in the global registry of acute coronary events</article-title>
          <source>Arch Intern Med</source>
          <year>2003</year>
          <volume>163</volume>
          <issue>19</issue>
          <fpage>2345</fpage>
          <lpage>2353</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.163.19.2345</pub-id>
        </element-citation>
        <mixed-citation>8 Granger CB, Robert J, Goldberg RJ, Dabbous O, Karen S, Pieper KS, et al. Global Registry of Acute Coronary Events Investigators Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345&#8211;53. doi: 10.1001/archinte.163.19.2345.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chesebro</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Knatterud</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Borer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Dalen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I findings, TIMI Study Group</article-title>
          <source>N Engl J Med.1985;312(4)</source>
          <year>1985</year>
          <volume>312</volume>
          <issue>14</issue>
          <fpage>932</fpage>
          <lpage>936</lpage>
          <pub-id pub-id-type="doi">10.1161/01.cir.76.1.142</pub-id>
        </element-citation>
        <mixed-citation>9 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, J Dalen, et al. The Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I findings, TIMI Study Group. N Engl J Med.1985;312(4) 1985;312(14):932&#8211;6. doi: 10.1161/01.cir.76.1.142.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henriques</surname>
              <given-names>JPS</given-names>
            </name>
            <name>
              <surname>Zijlstra</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>van Hof</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>de Boer</surname>
              <given-names>Menko-Jan</given-names>
            </name>
            <name>
              <surname>Dambrink</surname>
              <given-names>JHE</given-names>
            </name>
            <name>
              <surname>Jan-Henk</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade</article-title>
          <source>Circulation</source>
          <year>2003</year>
          <volume>107</volume>
          <issue>16</issue>
          <fpage>2115</fpage>
          <lpage>2119</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.0000065221.06430.ED</pub-id>
        </element-citation>
        <mixed-citation>10 Henriques JPS, Zijlstra F,van Hof AW, Menko-Jan de Boer, Dambrink JHE, Jan-Henk E, et al. Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade. Circulation. 2003;107(16):2115-9. doi: 10.1161/01.CIR.0000065221.06430.ED.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ting</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Bradley</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Wang Mr</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lichtman</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Nallamothu</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factors Associated With Longer Time From Symptom Onset to Hospital Presentation for Patients With ST-Elevation Myocardial Infarction</article-title>
          <source>Arch Intern Med</source>
          <year>2008</year>
          <volume>168</volume>
          <issue>9</issue>
          <fpage>959</fpage>
          <lpage>968</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.168.9.959</pub-id>
        </element-citation>
        <mixed-citation>11 Ting HH, Bradley EH, Wang Mr Y, Lichtman JH, Nallamothu BK, Sullivan MD., et al. Factors Associated With Longer Time From Symptom Onset to Hospital Presentation for Patients With ST-Elevation Myocardial Infarction. Arch Intern Med. 2008;168(9):959&#8211;68. doi: 10.1001/archinte.168.9.959.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyt&#246;</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sipil&#228;</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rautava</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Gender and in-hospital mortality of ST-segment elevation myocardial infarction (from a multihospital nationwide registry study of 31,689 patients)</article-title>
          <source>Am J Cardiol</source>
          <year>2015</year>
          <volume>115</volume>
          <issue>3</issue>
          <fpage>303</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjcard.2014.11.001</pub-id>
        </element-citation>
        <mixed-citation>12 Kyt&#246; V, Sipil&#228; J, Rautava P. Gender and in-hospital mortality of ST-segment elevation myocardial infarction (from a multihospital nationwide registry study of 31,689 patients). Am J Cardiol. 2015;115(3):303&#8211;6. doi: 10.1016/j.amjcard.2014.11.001</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#8217;Onofrio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Safdar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lichtman</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Strait</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Dreyer</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Geda</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sex differences in reperfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study</article-title>
          <source>Circulation</source>
          <year>2015</year>
          <volume>131</volume>
          <issue>15</issue>
          <fpage>1324</fpage>
          <lpage>1332</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.012293</pub-id>
        </element-citation>
        <mixed-citation>13 D&#8217;Onofrio G, Safdar B, Lichtman JH, Strait KM. Dreyer RP, Geda M, et al. Sex differences in reperfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study. Circulation 2015;131(15):1324&#8211;32. doi: 10.1161/CIRCULATIONAHA.114.012293.</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bugiardini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Fitchett</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Manfrini</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factors influencing underutilization of evidence-based therapies in women</article-title>
          <source>Eur Heart J</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>1337</fpage>
          <lpage>1344</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehr027</pub-id>
        </element-citation>
        <mixed-citation>14 Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, et al. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011;11:1337&#8211;44. doi: 10.1093/eurheartj/ehr027.</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jneid</surname>
              <given-names>Hani</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>Gregg C</given-names>
            </name>
            <name>
              <surname>Cannon</surname>
              <given-names>Christopher P</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>Adrian F</given-names>
            </name>
            <name>
              <surname>Palacios</surname>
              <given-names>Igor F</given-names>
            </name>
            <name>
              <surname>MareeJneid H</surname>
              <given-names>Andrew O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sex differences in medical care and early death after acute myocardial infarction</article-title>
          <source>Circulation</source>
          <year>2008</year>
          <volume>118</volume>
          <issue>25</issue>
          <fpage>2803</fpage>
          <lpage>2810</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.789800</pub-id>
        </element-citation>
        <mixed-citation>15 Hani Jneid, Gregg C Fonarow, Christopher P Cannon, Adrian F Hernandez, Igor F Palacios, Andrew O MareeJneid H, et al. Sex differences in medical care and early death after acute myocardial infarction. Circulation 2008;118(25):2803&#8211;10. doi: 10.1161/CIRCULATIONAHA.108.789800.</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawesson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Alfredsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mats</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Swahn</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Time trends in STEMI&#8212;improved treatment and outcome but still a gender gap: a prospective observational cohort study from the SWEDEHEART register</article-title>
          <source>BMJ Open</source>
          <year>2012</year>
          <volume>2</volume>
          <issue>2</issue>
          <elocation-id>e000726</elocation-id>
          <pub-id pub-id-type="doi">10.1136/bmjopen-2011-000726</pub-id>
        </element-citation>
        <mixed-citation>16 Lawesson SS, Alfredsson J, Mats F, Swahn E. Time trends in STEMI&#8212;improved treatment and outcome but still a gender gap: a prospective observational cohort study from the SWEDEHEART register. BMJ Open 2012;2(2):e000726. doi: 10.1136/bmjopen-2011-000726</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stuart</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sheifer</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Canos</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Weinfurt</surname>
              <given-names>Uk</given-names>
            </name>
            <name>
              <surname>Umesh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sex differences in coronary artery size assessed by intravascular ultrasound</article-title>
          <source>Am Heart J</source>
          <year>2000</year>
          <volume>139</volume>
          <issue>4</issue>
          <fpage>649</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="doi">10.1016/s0002-8703(00)90043-7</pub-id>
        </element-citation>
        <mixed-citation>17 Stuart E, Sheifer MR, Canos KP, Weinfurt Uk, Umesh K, Farrell A, et al. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J. 2000;139(4):649-53. doi: 10.1016/s0002-8703(00)90043-7.</mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petronio</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Musumeci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Limbruno</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Baglini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Amoroso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Merelli</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Coronary angioplasty in women: risk factors and sex-related differences in coronary anatomy evaluated with intravascular ultrasonography</article-title>
          <source>Ital Heart J</source>
          <year>2002</year>
          <supplement>Suppl</supplement>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>71</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">11899576</pub-id>
        </element-citation>
        <mixed-citation>18 Petronio AS, Musumeci G, Limbruno U, Baglini R, Amoroso G, Merelli A, et al. Coronary angioplasty in women: risk factors and sex-related differences in coronary anatomy evaluated with intravascular ultrasonography.Ital Heart J 2002;Suppl,;3(1):71-7. PMID: 11899576</mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keteepe-Arachi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular Disease in Women: Understanding Symptoms and Risk Factors</article-title>
          <source>Eur Cardiol</source>
          <year>2017</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>10</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.15420/ecr.2016:32:1</pub-id>
        </element-citation>
        <mixed-citation>19 Keteepe-Arachi T, Sharma S. Cardiovascular Disease in Women: Understanding Symptoms and Risk Factors. Eur Cardiol. 2017;12(1):10-3. doi: 10.15420/ecr.2016:32:1.</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mosca</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Berra</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bezanson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dolor</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Lloyd-Jones</surname>
              <given-names>DM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness-based guidelines for the prevention of cardiovascular disease in women&#8212;2011 update: a guideline from the American Heart Association</article-title>
          <source>Circulation</source>
          <year>2011</year>
          <volume>123</volume>
          <issue>11</issue>
          <fpage>1243</fpage>
          <lpage>1262</lpage>
          <pub-id pub-id-type="doi">10.1161/CIR.0b013e31820faaf8</pub-id>
        </element-citation>
        <mixed-citation>20 Mosca L, Benjamin EJ, Berra K, Bezanson J, Dolor RJ, Lloyd-Jones DM, et al.et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women&#8212;2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8.</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Boer</surname>
              <given-names>SPM</given-names>
            </name>
            <name>
              <surname>Roos-Hesselink</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>MAH</given-names>
            </name>
            <name>
              <surname>Lenzen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>van Geuns</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Regar</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Excess mortality in women compared to men after PCI in STEMI: an analysis of 11,931 patients during 2000-2009</article-title>
          <source>Int J Cardiol</source>
          <year>2014</year>
          <day>20</day>
          <volume>176</volume>
          <issue>2</issue>
          <fpage>456</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">25127966</pub-id>
        </element-citation>
        <mixed-citation>21 de Boer SPM, Roos-Hesselink J, van Leeuwen MAH, Lenzen MJ, van Geuns RJ, Regar E, et al. Excess mortality in women compared to men after PCI in STEMI: an analysis of 11,931 patients during 2000-2009. Int J Cardiol. 2014 20;176(2):456-63. PMID: 25127966</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huxley</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Woodward</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies</article-title>
          <source>BMJ</source>
          <year>2006</year>
          <volume>332</volume>
          <issue>7533</issue>
          <fpage>73</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.38678.389583.7C</pub-id>
        </element-citation>
        <mixed-citation>22 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ.2006.332(7533):73&#8211;8. doi:10.1136/bmj.38678.389583.7C.</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tonstad</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosvold</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Furu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Skurtveit</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001</article-title>
          <source>J Intern Med</source>
          <year>2004</year>
          <volume>255</volume>
          <issue>4</issue>
          <fpage>494</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01315.x</pub-id>
        </element-citation>
        <mixed-citation>23 Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med. 2004;255(4):494-502. doi:10.1111/j.1365-2796.2004.01315.x</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cull</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Neil</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Holman</surname>
              <given-names>RR</given-names>
            </name>
          </person-group>
          <article-title>Changing aspirin use in patients with type 2 diabetes in the UKPDS</article-title>
          <source>Diab Med</source>
          <year>2004</year>
          <volume>21</volume>
          <issue>12</issue>
          <fpage>1368</fpage>
          <lpage>1371</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1464-5491.2004.01328.x</pub-id>
        </element-citation>
        <mixed-citation>24 Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diab Med. 2004;21(12):1368-71. doi: 10.1111/j.1464-5491.2004.01328.x.</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campbell</surname>
              <given-names>Duncan J</given-names>
            </name>
            <name>
              <surname>Somaratne</surname>
              <given-names>Jithendra B</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>Alicia J</given-names>
            </name>
            <name>
              <surname>Prior</surname>
              <given-names>David L</given-names>
            </name>
            <name>
              <surname>Yii</surname>
              <given-names>Michael</given-names>
            </name>
            <name>
              <surname>Kenny</surname>
              <given-names>James F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease</article-title>
          <source>Hypertension</source>
          <year>2011</year>
          <volume>57</volume>
          <issue>2</issue>
          <fpage>186</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.110.165043</pub-id>
        </element-citation>
        <mixed-citation>25 Duncan J Campbell, Jithendra B Somaratne, Alicia J Jenkins, David L Prior, Michael Yii, James F Kenny, et al. Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. Hypertension 2011;57(2):186-192. doi:10.1161/HYPERTENSIONAHA.110.165043.</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milcent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dormont</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Durand-Zaleski</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database</article-title>
          <source>Circulation</source>
          <year>2007</year>
          <volume>115</volume>
          <issue>7</issue>
          <fpage>833</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.664979</pub-id>
        </element-citation>
        <mixed-citation>26 Milcent C, Dormont B, Durand-Zaleski I, Gabriel P. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. Circulation. 2007;115(7):833-9. doi: 10.1161/CIRCULATIONAHA.106.664979.</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantor</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Fitchett</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Borgundvaag</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ducas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Heffernan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Routine early angioplasty after fibrinolysis for acute myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <issue>26</issue>
          <fpage>2705</fpage>
          <lpage>2718</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0808276</pub-id>
        </element-citation>
        <mixed-citation>27 Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705-18. doi: 10.1056/NEJMoa0808276.</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mega</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Morrow</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Ost&#246;r</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dorobantu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Antman</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction</article-title>
          <source>Circulation</source>
          <year>2007</year>
          <volume>115</volume>
          <issue>22</issue>
          <elocation-id>2822e8</elocation-id>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.679548</pub-id>
        </element-citation>
        <mixed-citation>28 Mega JL, Morrow DA, Ost&#246;r E, Dorobantu M, Qin J, Antman EM, Braunwald E. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation. 2007;115(22):2822e8. doi: 10.1161/CIRCULATIONAHA.106.679548.</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kereiakes</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gibler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aufderheide</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the prehospital study group and the Cincinnati Heart Project</article-title>
          <source>Am Heart J</source>
          <year>1990</year>
          <volume>120</volume>
          <issue>4</issue>
          <fpage>773</fpage>
          <lpage>780</lpage>
          <pub-id pub-id-type="doi">10.1016/0002-8703(90)90192-z</pub-id>
        </element-citation>
        <mixed-citation>29 Kereiakes DJ, Weaver WD, Anderson JL, Feldman T, Gibler B, Aufderheide T, et al. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the prehospital study group and the Cincinnati Heart Project. Am Heart J. 1990;120(4):773-80. doi: 10.1016/0002-8703(90)90192-z.</mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henkel</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Witt</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Weston</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Meverden</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ventricular arrhythmias after acute myocardial infarction: a 20-year community study</article-title>
          <source>Am Heart J</source>
          <year>2006</year>
          <volume>151</volume>
          <issue>4</issue>
          <fpage>806</fpage>
          <lpage>812</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ahj.2005.05.015</pub-id>
        </element-citation>
        <mixed-citation>30 Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, et al. Ventricular arrhythmias after acute myocardial infarction: a 20-year community study. Am Heart J. 2006;151(4):806-12. doi: 10.1016/j.ahj.2005.05.015.</mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahimi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Watzlawek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Secknus</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hayerizadeh</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Niebauer</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment</article-title>
          <source>Eur Heart J</source>
          <year>2006</year>
          <volume>27</volume>
          <issue>14</issue>
          <fpage>1706</fpage>
          <lpage>1711</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehl100</pub-id>
        </element-citation>
        <mixed-citation>31 Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J.2006;27(14):1706-11. doi: 10.1093/eurheartj/ehl100.</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amin</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Spertus</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Buchanan</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Decker</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality</article-title>
          <source>Am Heart J</source>
          <year>2010</year>
          <volume>160</volume>
          <issue>6</issue>
          <fpage>1065</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ahj.2010.08.007</pub-id>
        </element-citation>
        <mixed-citation>32 Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, Decker C, et al. The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. Am Heart J. 2010;160(6):1065&#8211;71. doi: 10.1016/j.ahj.2010.08.007.</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joachim</surname>
              <given-names>H Ix</given-names>
            </name>
            <name>
              <surname>Shlipak</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Whooley</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The Heart and Soul Study</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2003</year>
          <volume>14</volume>
          <issue>12</issue>
          <fpage>3233</fpage>
          <lpage>3239</lpage>
          <pub-id pub-id-type="doi">10.1097/01.asn.0000095642.25603.7a</pub-id>
        </element-citation>
        <mixed-citation>33 Joachim H Ix, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The Heart and Soul Study. J Am Soc Nephrol. 2003;14(12):3233-9. doi: 10.1097/01.asn.0000095642.25603.7a.</mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turak</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Afsar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Siriopol</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yayla</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Oksu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cagli</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Severity of coronary artery disease is an independent risk factor for decline in kidney function</article-title>
          <source>Eur J Intern Med</source>
          <year>2016</year>
          <volume>33</volume>
          <fpage>93</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejim.2016.06.031</pub-id>
        </element-citation>
        <mixed-citation>34 Turak O, Afsar B, Siriopol D, Yayla C, Oksu F, Cagli K, et al. Severity of coronary artery disease is an independent risk factor for decline in kidney function. Eur J Intern Med. 2016;33:93-7. doi: 10.1016/j.ejim.2016.06.031.</mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vernino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>RD</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sejvar</surname>
              <given-names>JJR</given-names>
            </name>
            <name>
              <surname>Petty</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>O&#8217;Fallon</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cause-specific mortality after first cerebral infarction: a population-based study</article-title>
          <source>Stroke</source>
          <year>2003</year>
          <volume>34</volume>
          <issue>8</issue>
          <fpage>1828</fpage>
          <lpage>1832</lpage>
          <pub-id pub-id-type="doi">10.1161/01.STR.0000080534.98416.A0</pub-id>
        </element-citation>
        <mixed-citation>35 Vernino S, Brown Jr RD, Sejvar JJR, Petty GW, O&#8217;Fallon M. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke 2003;34(8):1828&#8211;32. doi: 10.1161/01.STR.0000080534.98416.A0.</mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhamoon</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Boden-Albala</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rundek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Paik</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Sacco</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study</article-title>
          <source>Stroke</source>
          <year>2007</year>
          <volume>38</volume>
          <issue>6</issue>
          <fpage>1752</fpage>
          <lpage>1758</lpage>
          <pub-id pub-id-type="doi">10.1161/STROKEAHA.106.480988</pub-id>
        </element-citation>
        <mixed-citation>36 Dhamoon MS, Tai W, Boden-Albala B, Rundek T, Paik MC, Sacco RL, et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke. 2007;38(6):1752&#8211;8. doi: 10.1161/STROKEAHA.106.480988.</mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miettinen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lehto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Salomaa</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>M&#228;h&#246;nen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niemel&#228;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haffner</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group</article-title>
          <source>Diabetes Care</source>
          <year>1998</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>69</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">9538972</pub-id>
        </element-citation>
        <mixed-citation>37 Miettinen H, Lehto S, Salomaa V, M&#228;h&#246;nen M, Niemel&#228; M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998; 21(1):69&#8211;75. PMID: 9538972</mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juutilainen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lehto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>R&#246;nnemaa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Py&#246;r&#228;l&#228;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Laakso</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Type 2 diabetes as a &#8220;coronary heart disease equivalent&#8221;: an 18-year prospective population-based study in Finnish subjects</article-title>
          <source>Diabetes Care</source>
          <year>2005</year>
          <volume>28</volume>
          <issue>12</issue>
          <fpage>2901</fpage>
          <lpage>2907</lpage>
          <pub-id pub-id-type="doi">10.2337/diacare.28.12.2901</pub-id>
        </element-citation>
        <mixed-citation>38 Juutilainen A, Lehto S, R&#246;nnemaa T, Py&#246;r&#228;l&#228; K, Laakso M. Type 2 diabetes as a &#8220;coronary heart disease equivalent&#8221;: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):2901-7. doi: 10.2337/diacare.28.12.2901.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S01" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmaco-invasive Strategy in Myocardial Infarction: Descriptive Analysis, Presentation of Ischemic Symptoms and Mortality Predictors</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-6746-8327</contrib-id>
          <name>
            <surname>Bianco</surname>
            <given-names>Henrique Tria</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Writing of the manuscript</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-4295-9151</contrib-id>
          <name>
            <surname>Povoa</surname>
            <given-names>Rui</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-5738-2623</contrib-id>
          <name>
            <surname>Izar</surname>
            <given-names>Maria Cristina</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <role>Statistical analysis</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alves</surname>
            <given-names>Claudia Maria Rodrigues</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Adriano Henrique Pereira</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-9603-6072</contrib-id>
          <name>
            <surname>Bombig</surname>
            <given-names>Maria Teresa Nogueira</given-names>
          </name>
          <role>Writing of the manuscript</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gon&#231;alves</surname>
            <given-names>Iran</given-names>
            <suffix>Jr</suffix>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luna</surname>
            <given-names>Br&#225;ulio</given-names>
            <suffix>Filho</suffix>
          </name>
          <role>Statistical analysis</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aguirre</surname>
            <given-names>Ana Caroline</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moraes</surname>
            <given-names>Pedro Ivo de Marqui</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2178-1518</contrib-id>
          <name>
            <surname>Almeida</surname>
            <given-names>Dirceu</given-names>
          </name>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreira</surname>
            <given-names>Fl&#225;vio Tocci</given-names>
          </name>
          <role>Statistical analysis</role>
          <role>Writing of the manuscript</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9774-4406</contrib-id>
          <name>
            <surname>Povoa</surname>
            <given-names>Fernando Focaccia</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stefanini</surname>
            <given-names>Edson</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caixeta</surname>
            <given-names>Adriano Mendes</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Statistical analysis</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bacchin</surname>
            <given-names>Amanda S.</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mois&#233;s</surname>
            <given-names>Valdir Ambr&#243;sio</given-names>
          </name>
          <role>Acquisition of data</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9911-4598</contrib-id>
          <name>
            <surname>Fonseca</surname>
            <given-names>Francisco A.H.</given-names>
          </name>
          <role>Conception and design of the research</role>
          <role>Acquisition of data</role>
          <role>Analysis and interpretation of the data</role>
          <role>Critical revision of the manuscript for important intellectual content</role>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
        </contrib>
        <aff id="aff3">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Universidade Federal de S&#227;o Paulo &#8211; Cardiologia, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
        <aff id="aff4">
          <label>2</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Universidade Federal de S&#227;o Paulo Escola Paulista de Medicina &#8211; Medicina, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><bold>Mailing Address: Henrique Tria Bianco</bold> &#8226; Universidade Federal de S&#227;o Paulo - Rua Loefgren, 1350. Postal Code - <postal-code>04040-001</postal-code>, S&#227;o Paulo, SP - Brazil E-mail: <email>henriquetria@uol.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background</title>
          <p>ST-segment elevation myocardial infarction (STEMI) is defined by symptoms accompanied by typical electrocardiogram changes. However, the characterization of ischemic symptoms is unclear, especially in subgroups such as women and the elderly.</p>
        </sec>
        <sec>
          <title>Objectives</title>
          <p>To analyze the typification of ischemic symptoms, temporal metrics and observe the occurrence of in-hospital outcomes, in the analysis of predictive scores, in patients with STEMI, in a drug-invasive strategy.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Study involving 2,290 patients. Types of predefined clinical presentations: typical pain, atypical pain, dyspnea, syncope. We measured the time between the onset of symptoms and demand for care and the interval between arrival at the medical unit and thrombolysis. Odds-ratios (OR; CI-95%) were estimated in a regression model. ROC curves were constructed for mortality predictors. The adopted significance level (alpha) was 5%.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Women had a high prevalence of atypical symptoms; longer time between the onset of symptoms and seeking care; delay between arrival at the emergency room and fibrinolysis. Hospital mortality was 5.6%. Risk prediction by Killip-Kimball classification: AUC: [0.77 (0.73-0.81)] in class &#8805;II. Subgroups studied [OR (CI-95%)]: women [2.06 (1.42-2.99); p=0.01]; chronic renal failure [3.39 (2.13-5.42); p&lt;0.001]; elderly [2.09 (1.37-3.19) p&lt;0.001]; diabetics [1.55 (1.04-2.29); p=0.02]; obese 1.56 [(1.01-2.40); p=0.04]: previous stroke [2.01 (1.02-3.96); p=0.04] correlated with higher mortality rates.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Despite higher mortality rates in some subgroups, significant disparity persists in women, with delays in symptom recognition and prompt thrombolysis. We highlight the applicability of the Killip-Kimball score in prediction, regardless of the clinical presentation.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>ST Elevation Myocardial Infarction</kwd>
        <kwd>Acute Coronay Syndrome</kwd>
        <kwd>Percutaneous Coronary Intervention/methods</kwd>
        <kwd>Thrombolytic, Therapy/methods</kwd>
        <kwd>Angina Pectoris</kwd>
        <kwd>Hospitalization</kwd>
        <kwd>Mortality</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Despite advances in reperfusion approaches, acute myocardial infarction continues to be the leading cause of death worldwide. Its diagnosis is considered when typical electrocardiographic (ECG) changes and/or the elevation of markers can be detected, notably troponins, which have received increasing attention as highly specific markers of myocardial injury. ST-segment elevation myocardial infarction (STEMI) is usually caused by acute coronary occlusion, secondary to plaque rupture and thrombosis, requiring early intervention.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Therefore, the management of STEMI must be performed as quickly as possible to prevent further damage to the myocardium and decrease the risk of complications and mortality. Although primary percutaneous coronary intervention (PCI) is considered a &#8220;gold standard&#8221; treatment, it is not sufficiently available, especially in developing countries. The STREAM study values a reperfusion strategy combining fibrinolytic therapy and immediate transfer to a tertiary center for rescue PCI in non-responders to fibrinolysis, as well as early diagnostic angiography and secondary PCI within 24 h after thrombolysis.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> However, some factors can influence the delay in seeking emergency assistance, such as the perception and recognition of acute ischemic symptoms. The interpretation of warning signs is the trigger that leads patients to seek medical attention, due to the severity of this potentially fatal condition. By contrast, pain must be seen as a multidimensional phenomenon involving physiological, sensory, and sociocultural aspects, and can be impacted by expectations within a cultural context.</p>
        <p>Risk stratification enables providers to identify the right level of care and services for distinct subgroups of patients. It is the process of assigning a risk status, then using this report to guide what care is provided and to improve overall health outcomes. Nevertheless, during the diagnostic process of myocardial infarction, based on clinical reports and ECG criteria, differences may appear regarding how the symptoms are referred to, particularly in specific subgroups, such as women or older age groups, presenting evidence and relevance of early recanalization, whose benefits become more discreet or even non-existent in late reperfusion.<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup> Additionally, there are still controversies and special interests regarding the performance of early mortality predictors in patients undergoing thrombolytic treatment in a pharmaco-invasive approach. Therefore, the present study considers the stratified assessment of ischemic symptoms, fundamentally associated with temporal metrics, including the time between the onset of symptoms and the search for medical care, the patients&#8217; medical needs between arrival at the emergency unit and the recognition of the acute condition, with the prompt installation of the reperfusion protocols. In the scenario of the pharmaco-invasive strategy, possible differences can also be speculated concerning the manner in which the symptoms appeared and pivotal times in some subgroups, considering the impact of late reperfusion on relevant clinical outcomes.</p>
        <p>Thus, our study aimed to examine the associations between the clinical presentation of ischemic symptoms and risk factors with cardiovascular outcomes in a cohort of STEMI patients during the hospitalization period, as well as perform an accurate analysis of risk prediction scores.</p>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <sec>
          <title>Study design and ethical statements</title>
          <p>Prospective and observational study, with a sample size defined by convenience, involving 2,290 STEMI patients who were consecutively admitted to a university hospital in the city of Sao Paulo, Brazil. All patients were initially submitted to thrombolytic therapy with tenecteplase (TNK) in hospital units or primary care centers and were then referred for coronary angiography. When appropriate, percutaneous coronary interventions were performed within 24 hours post-fibrinolysis, or immediately if rescue therapy was needed. This study complies with the Declaration of Helsinki; the local ethics committee approved the research protocol; and informed consent was obtained from all patients or their legal guardians. The study is registered in ClinicalTrials.gov (NCT02090712).</p>
        </sec>
        <sec>
          <title>Pharmaco-invasive strategy</title>
          <p>The pharmaco-invasive strategy is defined by fibrinolysis treatment with a bolus injection of TNK, with a weight-adjusted dose, followed by cardiac catheterization within 24 hours, even in stable patients with successful reperfusion, with the intention to treat the culprit lesion. After the STREAM trial results in June 2013, patients over 75 years of age received a half dose of tenecteplase (1/2 TNK). Upon diagnosis, the patients received acetylsalicylic acid and clopidogrel, as recommended by guidelines.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Rescue angioplasties were recommended by the local medical team due to ineffective thrombolysis in the treatment of an infarct-related artery (IRA). The term <italic>culprit lesion</italic> was used to designate the artery vessel responsible for the symptoms of the STEMI patient. In most cases, only culprit lesions were treated, that is, only IRA lesions were addressed directly through angioplasty and stent delivery. The present study counted on a centralized database, containing a demographic profile, clinical data, ECGs, treatments, time intervals, and in-hospital events. Thus, all relevant outcomes were systematically recorded and mortality rates were analyzed by independent observers.</p>
        </sec>
        <sec>
          <title>Definitions of clinical presentations</title>
          <p>The clinical presentation of acute ischemic symptoms was reported by the patients, and trained staff reviewed the data during the in-hospital period.</p>
          <list list-type="order">
            <list-item>
              <p>Typical Chest Pain: oppressive chest pain on the left side, which can be irradiated to the left upper limb, of great intensity and prolonged (longer than 20 minutes), which did not improve or had only partial relief with rest or sublingual nitrates. Irradiation to the mandible, right upper limb, back, shoulders, and epigastrium was also considered for this presentation. This group included patients with a concomitant presentation of dyspnea, or syncopal episode.</p>
            </list-item>
            <list-item>
              <p>Atypical Pain: pain in the right upper quadrant or epigastric region of the abdomen, dorsal, mandibular region, or another non-thoracic region, referred to as a twinge or burning of variable intensity, with prolonged duration (greater than 20 minutes). Included in this group were patients with a concomitant presentation of dyspnea or syncopal episodes.</p>
            </list-item>
            <list-item>
              <p>Dyspnea: this group included those patients who did not report chest pain but who complained of acute fatigue or worsening of this symptom within the last couple of hours. The subjective experience of respiratory distress, comprised of qualitatively different sensations with varying intensity was considered.</p>
            </list-item>
            <list-item>
              <p>Syncope: This symptom was considered for those patients who did not report chest pain but did report fainting or a sudden and transient loss of consciousness or any worsening within the last couple of hours.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Measured pivotal times</title>
          <list list-type="order">
            <list-item>
              <p>Time interval between the onset of persistent chest pain, or another representative complaint of ischemic symptoms, and the patient&#8217;s arrival at the primary health unit;</p>
            </list-item>
            <list-item>
              <p>Time interval between the patient&#8217;s arrival at the health unit and thrombolysis;</p>
            </list-item>
            <list-item>
              <p>Time interval between thrombolysis and coronary angiography.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Prediction scores</title>
          <p>Risk predictors used during first medical contact:</p>
          <list list-type="order">
            <list-item>
              <p>Killip-Kimball Classification (KK);<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
            </list-item>
            <list-item>
              <p>TIMI-Risk;<sup><xref ref-type="bibr" rid="B7">7</xref></sup></p>
            </list-item>
            <list-item>
              <p>GRACE score<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Angiographic variables</title>
          <p>Experienced interventional cardiologists performed angiographic analyses according to TIMI-flow score (epicardial coronary perfusion);<sup><xref ref-type="bibr" rid="B9">9</xref></sup> and Myocardial Blush Grade (MBG)<sup><xref ref-type="bibr" rid="B10">10</xref></sup> (myocardial tissue-level perfusion), thus obtaining TIMI-flow and MBG before and after the percutaneous intervention when applicable (named as initial and final scores). Complications inherent to the procedure have also been reported. The procedural strategy (thrombus aspiration, balloon dilatation, stent selection, and anticoagulation regimen) was left up to the discretion of the operator.</p>
        </sec>
        <sec>
          <title>Statistical analysis</title>
          <p>This study sought to achieve a prospective and consecutive data collection from a large population, in which current standard medical practice is applied in an organized network. Continuous variables were described as mean &#177; standard deviation (SD) or median and interquartile range [IQR (25th&#8211;75th percentiles)], according to the normality of the data. To assess the assumptions of normality, our study used the D&#8217;Agostino-Pearson test, developed to evaluate a large sample, and was confirmed through the visual inspection of scatter plots. Categorical variables were described as absolute and relative frequencies, and were examined by Pearson&#8217;s Chi-squared test. For comparisons of numerical variables between groups, the unpaired Student&#8217;s t-test or the Mann-Whitney U test was used when non-Gaussian distribution was assumed. A simple analysis of variance using the &#8220;t&#8221; test, or its non-parametric equivalents, were performed to observe the distribution and homoscedasticity of the values. To compare proportions between the groups, the <sup>&#967;</sup>&#178; (chi-square) test was used for independent samples. To assume an equality of variance between groups, adjustments were made using Levene&#8217;s test. The relative risk was determined by the ratio between carriers of a given variable and non-carriers. To analyze the relationship of some categorical variables and the outcomes, these were transformed into dichotomies. Thus, the proportions test (chi-square) was used to observe the independence between the univariates in order to obtain the odds ratios (ORs) in a correlation model between potentially predictive univariates and the outcomes. In multivariate statistics, the relationships of multiple variables were only verified for those deemed to be significant upon entry (variables with p &lt;0.10) so as to observe their degree of independence. The binary logistic regression model, by means of the maximum likelihood technique, was used, in which the dependent variable was dichotomous and the predictor variables were inserted by the stepwise model, considering the absence of collinearity by the VIF index (variance inflation factor), with the goodness of fit evaluated by the Hosmer-Lemeshow diagram. The predictor variables were analyzed simultaneously in such a way that the effect of each variable was adjusted in order to have an effect on the others. This regression model systematically adds the most significant variable or removes the least significant variable during each step. The standardized Crombach&#8217;s <sup>&#945;</sup> index was used to calculate the reliability of the TIMI-flow and MBG angiographic scores estimated by medical operators.</p>
          <p>Receiver Operating Characteristic (ROC) curves were constructed in order to determine the sensitivity and specificity of the in-hospital outcome prediction scores. The shape of a ROC curve and the area under the curve (AUC) aided in estimating how high the discriminative power of a test was. A perfect diagnostic test has an AUC of 1.0, whereas a non-discriminatory test has an area of 0.5. Other analyses were also applied, considering the likelihood ratios in the prediction of events. Thus, based on the likelihood ratios, the diagnostic odds ratio (DOR), a global measure of diagnostic accuracy, was calculated, that is, the ratio of the odds of positivity in subjects with the outcome to the odds in subjects without the outcome. Our study considered a p-value &lt;0.05 to be statistically significant in two-tailed tests. All analyses were performed using the SPSS, version 20 (IBM-SPSS Statistics, USA)<sup>&#174;</sup></p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <sec>
          <title>Clinical and epidemiological characteristics</title>
          <p><xref ref-type="table" rid="t5">Table 1</xref> shows that patients had a median (IQR) of 58 (50-65) years, and approximately 70% were male. Most patients were hypertensive and smokers, and nearly a third had diabetes. There was a small proportion of patients who presented prior events, such as myocardial infarction, surgical or percutaneous revascularization, and prior stroke. The elderly group were those aged &#8805;60 years. The risk predictors included data on the patient&#8217;s medical history and risk factors, which were reviewed during hospital admission. This study also provides data on hemodynamic variables obtained in the emergency room, such as laboratory data (necrosis and biochemical markers) (<xref ref-type="table" rid="t6">Table. 2</xref>).</p>
          <table-wrap id="t5">
            <label>Table 1</label>
            <caption>
              <title>Baseline characteristics of the studied cohort</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="50%">
                <col/>
                <col/>
              </colgroup>
              <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#76B4CF">
                  <th style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Variables</th>
                  <th style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#76B4CF">
                  <th align="left" valign="middle">Epidemiological</th>
                  <th align="center" valign="middle">Measures</th>
                </tr>
              </thead>
              <tbody style="border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Age; md (IQR) - years</td>
                  <td align="center" valign="middle">58 (50-65)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Women: md (IQR) - years</td>
                  <td align="center" valign="middle">60 (52-68)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Men: md (IQR) - years</td>
                  <td align="center" valign="middle">57 (49-64)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Elderly (&#8805;60 years), n (%)</td>
                  <td align="center" valign="middle">998 (43,6)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="2">Gender; n (%)</td>
                  <td align="center" valign="middle">Male: 1607 (70.2)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Female: 683(29.8)</td>
                </tr>
                <tr style="background-color:#76B4CF">
                  <td align="left" valign="middle">
                    <bold>Habits &#8211; Addictions</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Measures</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Smoking, n (%)</td>
                  <td align="center" valign="middle">1472 (64.3)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Alcoholism, n (%)</td>
                  <td align="center" valign="middle">304 (13.3)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Illicit drugs, n (%)</td>
                  <td align="center" valign="middle">97 (4.2)</td>
                </tr>
                <tr style="background-color:#76B4CF">
                  <td align="left" valign="middle">
                    <bold>Clinics</bold>
                  </td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Obesity, n (%)</td>
                  <td align="center" valign="middle">481 (21.0)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN10">*</xref>BMI, Kg/m<sup>2</sup>; md (IQR)</td>
                  <td align="center" valign="middle">26 (23.8-29.3)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Arterial Hypertension, n (%)</td>
                  <td align="center" valign="middle">1405 (61.4)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Diabetes mellitus, n (%)</td>
                  <td align="center" valign="middle">661 (28.9)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Dyslipidemia, n (%)</td>
                  <td align="center" valign="middle">1133 (49.5)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Hypothyroidism, n (%)</td>
                  <td align="center" valign="middle">145 (6.3)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Chronic kidney disease, n (%)</td>
                  <td align="center" valign="middle">187 (8.2)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Peripheral arterial disease, n (%)</td>
                  <td align="center" valign="middle">117 (5.1)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Prior Stroke, n (%)</td>
                  <td align="center" valign="middle">99 (4.3)</td>
                </tr>
                <tr style="background-color:#76B4CF">
                  <td align="left" valign="middle">
                    <bold>Chronic coronary syndrome</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Measures</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Prior myocardial infarction, n (%)</td>
                  <td align="center" valign="middle">242 (10.6)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Prior coronary angioplasty, n (%)</td>
                  <td align="center" valign="middle">129 (5.6)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Prior surgical myocardial revascularization, n (%)</td>
                  <td align="center" valign="middle">45 (2)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN9">
                <p>Notes: Data on medical history and comorbidities were derived from physician interviews. Demographic information and risk factor profiles were reported by patients, and trained staff reviewed the data during hospitalization. Data are expressed as median (md) and interquartile range (IQR), and categorical variables as frequency (%). For age comparison between genders, the Mann-Whitney non-parametric test was used. Chronic kidney disease (CKD) was estimated by the Modification of Diet in Renal Disease (MDRD) equation and defined when the estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup>; obesity when BMI &#8805;30; hypertension defined by the use of antihypertensive drugs or systolic blood pressure &#8805;140 mmHg and/or diastolic blood pressure &#8805;90 mmHg. Smoking was defined for both ex-smoker and current smokers; dyslipidemia was defined by the use of specific drugs or total cholesterol &#8805;200 mg/dL, or triglycerides &#8805;150 mg/dL; diabetes was defined as specific treatment or glycated hemoglobin (HbA1c) &#8805;6.5%.</p>
              </fn>
              <fn id="TFN10">
                <label>*</label>
                <p>BMI: Body mass index.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="t6">
            <label>Table 2</label>
            <caption>
              <title>Clinical and hemodynamic characteristics, prediction scores, and pivotal times were obtained during the first medical contact and during the period of hospital stay</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="50%">
                <col/>
                <col/>
              </colgroup>
              <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#76B4CF">
                  <th align="left" valign="middle">Variables obtained during the first medical contact</th>
                  <th align="center" valign="middle">Measures</th>
                </tr>
              </thead>
              <tbody style="border-bottom: thin solid; border-color: #000000">
                <tr>
                  <td align="left" valign="middle">
                    <italic>Hemodynamic variables</italic>
                  </td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Systolic blood pressure, mmHg; md (IQR)</td>
                  <td align="center" valign="middle">130 (115-150)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Diastolic blood pressure, mmHg; md (IQR)</td>
                  <td align="center" valign="middle">80 (70-93)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Heart rate, md (IQR)</td>
                  <td align="center" valign="middle">76 (66-90)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="4">Killip-Kimball classification, n (%)</td>
                  <td align="center" valign="middle">Killip-Kimball &#8211; I: 1670 (72.0)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball &#8211; II: 362 (15.8)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball &#8211; III: 52 (2.3)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball &#8211; IV: 203 (8.0)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle" rowspan="5"><bold>Clinical presentation</bold><break/>(main symptom), n (%)</td>
                  <td align="center" valign="middle">Typical Pain: 1939 (88.5)</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Atypical Pain: 166 (7.6)</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Dyspnea: 38 (1.7)</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Syncope: 26 (1.2)</td>
                </tr>
                <tr>
                  <td align="center" valign="middle"><xref ref-type="table-fn" rid="TFN12">*</xref> Some patients (4%) with more than 1 reported symptom</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">
                    <bold>Risk Scores</bold>
                  </td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">TIMI-Risk, (0-14); md (IQR)</td>
                  <td align="center" valign="middle">3 (2-5)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Grace-escore; md (IQR)</td>
                  <td align="center" valign="middle">135 (115-160)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">
                    <bold>Pivot Times</bold>
                  </td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Pain-Health Unit, min; md (IQR)</td>
                  <td align="center" valign="middle">120 (60-220)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Pain-Needle, min; md (IQR)</td>
                  <td align="center" valign="middle">222 (140-345)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Door-Needle, min; md (IQR)</td>
                  <td align="center" valign="middle">71 (42-135)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Lysis-Angiography, hours; md (IQR)</td>
                  <td align="center" valign="middle">12 (5,67-23)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Variables obtained during the hospital period</td>
                  <td align="center" valign="middle">Measures</td>
                </tr>
                <tr style="background-color:#76B4CF">
                  <td align="left" valign="middle">Necrosis biomarkers</td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Initial troponin, mg/L; md (IQR)</td>
                  <td align="center" valign="middle">2655 (538-7967)</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Maximum troponin, mg/L; md (IQR)</td>
                  <td align="center" valign="middle">4718 (1481-9842)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">
                    <bold>Laboratory variables</bold>
                  </td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Hemoglobin / Hematocrit, g/dL / %; m &#177; SD</td>
                  <td align="center" valign="middle">14.37 &#177; 2,09 / 42.92 &#177; 12.56</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Blood glucose / Glycated hemoglobin, mg/dL / %; md (IQR)</td>
                  <td align="center" valign="middle">122 (102-160) / 6 (5.6-6.8)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Total Cholesterol, mg/dL; md (IQR)</td>
                  <td align="center" valign="middle">191 (157-225)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">HDL-C, mg/dL; md (IQR)</td>
                  <td align="center" valign="middle">37 (25-46)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">LDL-C, mg/dL; md (IQR)</td>
                  <td align="center" valign="middle">110 (60-142)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Triglycerides, mg/dL; md (IQR)</td>
                  <td align="center" valign="middle">118 (77-175)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN12">*</xref>AST, u/L; md (IQR)</td>
                  <td align="center" valign="middle">144 (63-280)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN13">&#8224;</xref>ALT, u/L; md (IQR)</td>
                  <td align="center" valign="middle">43 (27-72)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Creatinine, mg/dL; md (IQR)</td>
                  <td align="center" valign="middle">0,9 (0.74-1.10)</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Estimated Glomerular Filtration Rate, (MDRD); md (IQR)</td>
                  <td align="center" valign="middle">85 (64-107)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN11">
                <p>Notes: Data are expressed as median (md) and interquartile range (IQR), or mean and standard deviation (m &#177; sd), and categorical variables are presented as frequency (%). Time metrics are expressed in minutes (min). Estimated Glomerular Filtration Rate by Modification of Diet in Renal Disease (MDRD)</p>
              </fn>
              <fn id="TFN12">
                <label>*</label>
                <p>AST: aspartate aminotransferase</p>
              </fn>
              <fn id="TFN13">
                <label>&#8224;</label>
                <p>ALT: alanine aminotransferase.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec>
          <title>Prediction scores, clinical presentation and pivotal times</title>
          <p>In the analysis of ischemic symptoms, most patients reported chest pain defined as typical, which may or may not be associated with dyspnea or syncope. Angina prior to the event was present in 28%, which was more prevalent in patients with prior myocardial infarction. Women showed a high frequency of atypical symptoms, such as dyspnea and syncope, as shown in <xref ref-type="table" rid="t7">Table 3</xref>.</p>
          <table-wrap id="t7">
            <label>Table 3</label>
            <caption>
              <title>Variables associated with the type of clinical presentation in a univariate model and after multivariate adjustments in multinomial logistic regression</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="20%">
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#76B4CF">
                  <th align="left" valign="middle">Model without adjustments</th>
                  <th align="center" valign="middle">Typical Pain</th>
                  <th align="center" valign="middle">Atypical Pain</th>
                  <th align="center" valign="middle">Dyspnea</th>
                  <th align="center" valign="middle">Syncope</th>
                </tr>
              </thead>
              <tbody style="border-bottom: thin solid; border-color: #000000">
                <tr>
                  <td align="left" valign="middle">Variables</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle"/>
                  <td align="center" valign="middle">n = 1939</td>
                  <td align="center" valign="middle">n = 166</td>
                  <td align="center" valign="middle">n = 38</td>
                  <td align="center" valign="middle">n = 26</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Male</td>
                  <td align="center" valign="middle">0.95 <break/>(0.71-1.27), p=0.74</td>
                  <td align="center" valign="middle">1.05 <break/>(0.79-1.40), p=0.73</td>
                  <td align="center" valign="middle"><bold>0.51</bold><break/>(0.27-0.96), p=0.026</td>
                  <td align="center" valign="middle"><bold>0.39</bold><break/>(0.18-0.83), p=0.018</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Obesity</td>
                  <td align="center" valign="middle">1.07 <break/>(0.78-1.50), p=0.65</td>
                  <td align="center" valign="middle">0.92 <break/>(0.67-1.28), p=0.65</td>
                  <td align="center" valign="middle"><bold>0.30</bold><break/>(0.09-0.98), p=0.02</td>
                  <td align="center" valign="middle">0.29 <break/>(0.07-1.26), p=0.09</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Alcoholism</td>
                  <td align="center" valign="middle">0.80 <break/>(0.56-1.15), p=0.24</td>
                  <td align="center" valign="middle">1.24 <break/>(0.86-1.78), p=0.24</td>
                  <td align="center" valign="middle">1.15 <break/>(0.48-2.77), p=0.44</td>
                  <td align="center" valign="middle">1.49 <break/>(0.56-3.97), p=0.39</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Hypertension</td>
                  <td align="center" valign="middle">0.96 <break/>(0.73-1.26), p=0.78</td>
                  <td align="center" valign="middle">1.03 <break/>(0.79-1.35), p=0.79</td>
                  <td align="center" valign="middle">1.31 <break/>(0.67-2.56), p=0.26</td>
                  <td align="center" valign="middle">0.67 <break/>(0.31-1.44), p =0.32</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Dyslipidemia</td>
                  <td align="center" valign="middle"><bold>1.39</bold><break/>(1.07-1.81), p=0.013</td>
                  <td align="center" valign="middle"><bold>0.71</bold><break/>(0.55-0.93), p=0.013</td>
                  <td align="center" valign="middle">1.25 <break/>(0.66-2.35), p=0.52</td>
                  <td align="center" valign="middle"><bold>0.35</bold><break/>(0.15-0.84), p =0.019</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Prior myocardial infarction</td>
                  <td align="center" valign="middle">1.05 <break/>(0.68-1.61), p=0.81</td>
                  <td align="center" valign="middle">0.95 <break/>(0.62-1.46), p=0.82</td>
                  <td align="center" valign="middle"><bold>3.31</bold><break/>(1.63-6.72), p=0.002</td>
                  <td align="center" valign="middle">0.67 <break/>(0.16-2.86), p =0.59</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Prior Stroke</td>
                  <td align="center" valign="middle">0.75 <break/>(0.42-1.34), p=0.34</td>
                  <td align="center" valign="middle">1.32 <break/>(0.74-2.37), p=0.34</td>
                  <td align="center" valign="middle">1.82 <break/>(0.55-6.00), p=0.24</td>
                  <td align="center" valign="middle">0.85 <break/>(0.11-6.32), p =0.87</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Peripheral artery disease</td>
                  <td align="center" valign="middle">0.78 <break/>(0.45-1.35), p=0.30</td>
                  <td align="center" valign="middle">1.27 <break/>(0.74-2.20), p=0.38</td>
                  <td align="center" valign="middle">1.52 <break/>(0.46-5.00), p=0.45</td>
                  <td align="center" valign="middle">0.71 <break/>(0.09-5.29), p =0.74</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Chronic kidney disease</td>
                  <td align="center" valign="middle"><bold>0.53</bold><break/>(0.35-0.79), p=0.002</td>
                  <td align="center" valign="middle"><bold>1.88</bold><break/>(1.26-2.80), p=0.002</td>
                  <td align="center" valign="middle"><bold>4.47</bold><break/>(2.19-9.10), p&lt;0.001</td>
                  <td align="center" valign="middle">1.97 <break/>(0.67-5.77), p =0.27</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Smoking</td>
                  <td align="center" valign="middle">1.17 <break/>(0.90-1.53), p=0.23</td>
                  <td align="center" valign="middle">0.85 <break/>(0.65-1.11), p=0.23</td>
                  <td align="center" valign="middle">1.15 <break/>(0.59-2.25), p=0.74</td>
                  <td align="center" valign="middle">0.59 <break/>(0.27-1.27), p =0.22</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Diabetes</td>
                  <td align="center" valign="middle">0.95 <break/>(0.72-1.27), p=0.76</td>
                  <td align="center" valign="middle">1.04 <break/>(0.78-1.39), p=0.75</td>
                  <td align="center" valign="middle"><bold>2.26</bold><break/>(1.21-4.24), p=0.013</td>
                  <td align="center" valign="middle">0.70 <break/>(0.28-1.74), p =0.52</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td style="border-bottom: thin solid; border-color: #000000" align="left" valign="middle">Elderly</td>
                  <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">0.87 <break/>(0.67-1.13), p=0.32</td>
                  <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">1.14 <break/>(0.88-1.48), p=0.32</td>
                  <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">1.77 <break/>(0.94-3.33), p=0.07</td>
                  <td style="border-bottom: thin solid; border-color: #000000" align="center" valign="middle">0.76 <break/>(0.34-1.66) p =0.56</td>
                </tr>
                <tr style="background-color:#76B4CF">
                  <td align="left" valign="middle">
                    <bold>Adjusted model</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Typical Pain</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Atypical Pain</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Dyspnea</bold>
                  </td>
                  <td align="center" valign="middle">
                    <bold>Syncope</bold>
                  </td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Variable</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                  <td align="center" valign="middle"><bold>Odds-ratio</bold><break/>(95% CI), p-value</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Males</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">0.51 <break/>(0.26-0.97), p=0.04</td>
                  <td align="center" valign="middle">0.32 <break/>(0.15-0.70), p=0.005</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Obesity</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">0.29 <break/>(0.08-0.95), p =0.04</td>
                  <td align="center" valign="middle">NA</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Dyslipidemia</td>
                  <td align="center" valign="middle"><bold>1.44</bold><break/>(1.10-1.87), p=0.007</td>
                  <td align="center" valign="middle"><bold>0.69</bold><break/>(0.53-0.90), p =0.007</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle"><bold>0.36</bold><break/>(0.15-0.87), p=0.02</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Prior myocardial infarction</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">2.68 <break/>(1.28-5.58), p=0.008</td>
                  <td align="center" valign="middle">NA</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Chronic kidney disease</td>
                  <td align="center" valign="middle"><bold>0.50</bold><break/>(0.34-0.75), p=0.001</td>
                  <td align="center" valign="middle"><bold>1.97</bold><break/>(1.32-2.94), p=0.001</td>
                  <td align="center" valign="middle"><bold>3.33</bold><break/>(1.59-6.98), p=0.001</td>
                  <td align="center" valign="middle">NA</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Diabetes Mellitus</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle">NA</td>
                  <td align="center" valign="middle"><bold>1.93</bold><break/>(1.01-3.71), p=0.04</td>
                  <td align="center" valign="middle">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN14">
                <p>Notes: Data are expressed for (OR; 95% CI. p-value). In the multivariate analysis the predictor variables were analyzed simultaneously, so that the effect of each variable was adjusted for the effect of the others. Bold indicates statistical significance. Chronic kidney disease (CKD) was estimated by Modification of Diet in Renal Disease (MDRD); elderly: age &#8805;60 years. Bold indicates statistical significance. NA: not applicable.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Women presented a delay between the patient&#8217;s arrival at the emergency unit and the beginning of treatment: [women (2 h:17 min.) <italic>vs</italic> men (1 h:58 min.), p=0.021]. The stratified time (&#8805;240 min.) to receive treatment was favorable to the males: [OR 0.73; 95% CI (0.55-0.98), p=0.03]. Another relevant finding was the longer time interval between the onset of symptoms and the search for medical care among women: [women: (3 h:14 min.) vs men (2 h:48 min.), p=0.008]. During this period, diabetic women presented a longer time interval between the onset of symptoms and thrombolysis, including the arrival at the emergency unit at the beginning of treatment (pain-thrombolysis time), especially when compared to non-diabetic men (<xref ref-type="fig" rid="f4">Figure 1</xref>).</p>
          <fig id="f4">
            <label>Figure 1</label>
            <caption>
              <title>Time metrics related to gender and presence or absence of diabetes. Note. Pain-needle time expressed as mean (minutes). * Significant p-value when comparing non-diabetic men versus women with diabetes.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf01-en.tif"/></fig>
          <p>Most patients were in a low functional class, according to the KK score: [I (73%), II (16.3%), III (2.2%), and IV (8.6%)]; low-risk profile in the TIMI-Risk predictions score: [3, IQR (2-5)]; and GRACE: [136, IQR (117-161)]. Approximately 24% of the patients were referred for rescue angioplasty, as judged by the local medical team, for not achieving criteria for successful initial reperfusion therapy.</p>
        </sec>
        <sec>
          <title>Angiographic findings (culprit artery)</title>
          <list list-type="order">
            <list-item>
              <p>left anterior descending artery (LAD): 46.3%; 2) right coronary artery (RCA): 32.1%; 3) left circumflex artery (LCX): 6.1%; 4) left main coronary artery (LMCA): 0.4%; 5) posterior descending artery (PDA): 0.3%; 6) posterior ventricular branch (PV): 0.9%; 7) left marginal branch: 1.0%; 8) diagonal branch: 0.7%; 9) unidentified artery: 12.1%. The subgroup analysis found no significant associations between the culprit artery and prior risk factors, nor with the initial clinical presentation of ischemic symptoms.</p>
            </list-item>
          </list>
          <p>The TIMI-flow and MBG (initial and final) scores were recorded, ranked from 0 to 3: [TIMI-initial flow: (3)] and [MBG-initial: (3)] in approximately 60% and 42%, respectively. When these post-percutaneous procedure scores were analyzed, the [TIMI-final flow: (3)] and the [MBG-final: (3)] rates were: 78% and 58%, respectively, with a high level of reliability: Crombach&#8217;s <bold>&#945;</bold> =0.88.</p>
        </sec>
        <sec>
          <title>Outcomes associated with complications in the hemodynamics laboratory and by the index event</title>
          <p>The average length of hospital stay was 2.0 &#177; 1.3 days, from admission to tertiary hospital up to discharge or transference to a counter-referenced hospital to continue the treatment. A longer hospital stay was observed in the elderly group: [1.9 days (non-elderly) <italic>vs.</italic> 2.3 days (elderly), p=0.004] and notably in the group of patients who required replacement blood products due to bleeding: [1.9 days (without bleeding) vs. 3.4 days (major bleeding), p=0.004].</p>
          <p>The present study recorded the frequency of complications during the angiographic procedure, as well as those observed during the hospitalization period. These complications included important events, such as coronary dissection or rupture, among others, such as clinical complications, arrhythmias, and bleeding at the puncture site. Although infrequent, major bleeding was independently associated with in-hospital mortality. Higher bleeding rates were observed in the elderly group: [OR: 1.86; 95% CI (1.04-3.16), p=0.023].</p>
        </sec>
        <sec>
          <title>Predictors and variables associated with mortality rates</title>
          <p>The in-hospital mortality rate was 5.6%, with 128 deaths; of these, 23 (17.9%) occurred in the hemodynamics laboratory, with electrical instability or mechanical complications being the most prevalent and with a higher incidence occurring in the rescue group (11.5% <italic>vs.</italic> 2.4%). Regarding epidemiological characteristics and risk factors, a similar distribution of the analyzed variables was observed among surviving patients, when compared with those who died during the hospital period, except for the GRACE score, which showed higher values in patients who died: [134 (115-157) <italic>vs.</italic> 202 (155-233), p&lt;0.001]. The GRACE score (median score 136) showed good sensitivity but low specificity [sensitivity: 0.86%; specificity: 0.53%]. The TIMI-Risk Prediction Score (median score 3) presented the following: sensitivity: 0.87%; specificity: 0.57% (<xref ref-type="table" rid="t8">Table 4</xref>).</p>
          <table-wrap id="t8">
            <label>Table 4</label>
            <caption>
              <title>Clinical and epidemiological variables between the &#8220;survivor&#8221; and the &#8220;death&#8221; groups</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="25%">
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead style="border-top: thin solid; border-bottom: thin solid; border-color: #000000">
                <tr style="background-color:#76B4CF">
                  <th align="left" valign="middle"/>
                  <th align="center" valign="middle">Survivor group</th>
                  <th align="center" valign="middle">Death group</th>
                  <th align="center" valign="middle">p-value</th>
                </tr>
              </thead>
              <tbody style="border-bottom: thin solid; border-color: #000000">
                <tr>
                  <td align="left" valign="middle">
                    <bold>Variables</bold>
                  </td>
                  <td align="center" valign="middle">2162 (94.4%)</td>
                  <td align="center" valign="middle">128 (5.6%)</td>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">
                    <bold>Epidemiological</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Age, years:</td>
                  <td align="center" valign="middle">58 (50-66)</td>
                  <td align="center" valign="middle">56 (48-65)</td>
                  <td align="center" valign="middle">
                    <bold>0.047</bold>
                  </td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Male gender:</td>
                  <td align="center" valign="middle">Homens: 71.1%</td>
                  <td align="center" valign="middle">Homens: 53.2%</td>
                  <td align="center" valign="middle">
                    <bold>0.02</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle">
                    <bold>Risk Scores</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="4">Killip-Kimball, (%):</td>
                  <td align="center" valign="middle">Killip-Kimball - I: 75.6%</td>
                  <td align="center" valign="middle">Killip-Kimball- I: 20.6%</td>
                  <td align="center" valign="middle">0.09</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball - II: 16.4%</td>
                  <td align="center" valign="middle">Killip-Kimball- II: 7.9%</td>
                  <td align="center" valign="middle">0.42</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball - III: 2.2%</td>
                  <td align="center" valign="middle">Killip-Kimball- III: 4.8%</td>
                  <td align="center" valign="middle">0.96</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Killip-Kimball - IV: 5.7%</td>
                  <td align="center" valign="middle">Killip-Kimball- IV: 66.5%</td>
                  <td align="center" valign="middle">0.08</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">TIMI-Risk:</td>
                  <td align="center" valign="middle">3 (2-5)</td>
                  <td align="center" valign="middle">6 (5-8.2)</td>
                  <td align="center" valign="middle">0.26</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">GRACE-score:</td>
                  <td align="center" valign="middle">134 (115-157)</td>
                  <td align="center" valign="middle">202 (155-233)</td>
                  <td align="center" valign="middle">
                    <bold>p &lt;0.001</bold>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="middle">
                    <bold>ECG-variables</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="3">ECG wall</td>
                  <td align="center" valign="middle">anterior wall</td>
                  <td align="center" valign="middle">anterior wall</td>
                  <td align="center" valign="middle">anterior wall</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">inferior wall</td>
                  <td align="center" valign="middle">inferior wall</td>
                  <td align="center" valign="middle">inferior wall</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">lateral wall</td>
                  <td align="center" valign="middle">lateral wall</td>
                  <td align="center" valign="middle">lateral wall</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">
                    <bold>Hemodynamic Variables</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="4">Infarct-related artery:</td>
                  <td align="center" valign="middle">ADA: 45.5%</td>
                  <td align="center" valign="middle">ADA: 38.9%</td>
                  <td align="center" valign="middle" rowspan="4">0.84</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">ACD: 32.5%</td>
                  <td align="center" valign="middle">ACD: 36.5%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">ACX: 6%</td>
                  <td align="center" valign="middle">ACX: 10.3%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Others: 22.4%</td>
                  <td align="center" valign="middle">Others: 14.3%</td>
                </tr>
                <tr>
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN17">&#8224;</xref>Left ventricular ejection fraction (LVEF):</td>
                  <td align="center" valign="middle">50 (40-59)</td>
                  <td align="center" valign="middle">49 (40-60)</td>
                  <td align="center" valign="middle">0.17</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="4">Initial TIMI-flow:</td>
                  <td align="center" valign="middle">TIMI-0: 19.6%</td>
                  <td align="center" valign="middle">TIMI-0: 36.8%</td>
                  <td align="center" valign="middle" rowspan="4">0.97</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">TIMI-1: 3.3%</td>
                  <td align="center" valign="middle">TIMI-1: 11.3%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">TIMI-2: 15.4%</td>
                  <td align="center" valign="middle">TIMI-2: 17%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">TIMI-3: 61.7%</td>
                  <td align="center" valign="middle">TIMI-3: 34.9%</td>
                </tr>
                <tr>
                  <td align="left" valign="middle" rowspan="4">Final TIMI-flow:</td>
                  <td align="center" valign="middle">TIMI-0: 4.6%</td>
                  <td align="center" valign="middle">TIMI-0: 19.8%</td>
                  <td align="center" valign="middle" rowspan="4">0.10</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">TIMI-1: 1.2%</td>
                  <td align="center" valign="middle">TIMI-1: 4.7%</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">TIMI-2: 14.1%</td>
                  <td align="center" valign="middle">TIMI-2: 24.5%</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">TIMI-3: 80.1%</td>
                  <td align="center" valign="middle">TIMI-3: 50.9%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle" rowspan="4">Initial myocardial Blush-grade:</td>
                  <td align="center" valign="middle">Blush-0: 40.8%</td>
                  <td align="center" valign="middle">Blush-0: 71.7%</td>
                  <td align="center" valign="middle" rowspan="4">0.77</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Blush-1: 3.8%</td>
                  <td align="center" valign="middle">Blush-1: 2.8%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Blush-2: 2.6%</td>
                  <td align="center" valign="middle">Blush-2: 1.9%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="center" valign="middle">Blush-3: 52.8%</td>
                  <td align="center" valign="middle">Blush-3: 23.6%</td>
                </tr>
                <tr>
                  <td align="left" valign="middle" rowspan="4">Final myocardial Blush-grade:</td>
                  <td align="center" valign="middle">Blush-0: 24.7%</td>
                  <td align="center" valign="middle">Blush-0: 61%</td>
                  <td align="center" valign="middle" rowspan="4">0.39</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Blush-1: 8.8%</td>
                  <td align="center" valign="middle">Blush-1: 9.5%</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Blush-2: 6.1%</td>
                  <td align="center" valign="middle">Blush-2: 5.7%</td>
                </tr>
                <tr>
                  <td align="center" valign="middle">Blush-3: 60.4%</td>
                  <td align="center" valign="middle">Blush-3: 23.8%</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">
                    <bold>Laboratory Variables</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr>
                  <td align="left" valign="middle">Initial troponin (at baseline):</td>
                  <td align="center" valign="middle">2704 (618-7889)</td>
                  <td align="center" valign="middle">3413 (280-11506)</td>
                  <td align="center" valign="middle">0.83</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Maximum troponin:</td>
                  <td align="center" valign="middle">4820 (1661-9796)</td>
                  <td align="center" valign="middle">7925 (1145-1774)</td>
                  <td align="center" valign="middle">0.80</td>
                </tr>
                <tr>
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN16">*</xref>eGFR, (MDRD):</td>
                  <td align="center" valign="middle">86 (67-107)</td>
                  <td align="center" valign="middle">91 (66-111)</td>
                  <td align="center" valign="middle">0.62</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Hemoglobin:</td>
                  <td align="center" valign="middle">14.5 (13.3-15.7)</td>
                  <td align="center" valign="middle">13.7 (12.5-15.1)</td>
                  <td align="center" valign="middle">0.05</td>
                </tr>
                <tr>
                  <td align="left" valign="middle">Hematocrit:</td>
                  <td align="center" valign="middle">42.9 (39.6-46.2)</td>
                  <td align="center" valign="middle">41 (37.9-45.5)</td>
                  <td align="center" valign="middle">0.14</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">
                    <bold>Pivot Times</bold>
                  </td>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                  <td align="center" valign="middle"/>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Pain-Needle Time, (min):</td>
                  <td align="center" valign="middle">220 (140-345)</td>
                  <td align="center" valign="middle">245 (150-516)</td>
                  <td align="center" valign="middle">0.08</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle">Door to Needle Time, (min):</td>
                  <td align="center" valign="middle">75 (45-135)</td>
                  <td align="center" valign="middle">78.5 (45-163.7)</td>
                  <td align="center" valign="middle">0.12</td>
                </tr>
                <tr style="background-color:#C7DFEC">
                  <td align="left" valign="middle"><xref ref-type="table-fn" rid="TFN18">&#8225;</xref>Lyse-CATHETERISM TIME, (hours):</td>
                  <td align="center" valign="middle">11 (5-22)</td>
                  <td align="center" valign="middle">11 (5-21.7)</td>
                  <td align="center" valign="middle">0.43</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN15">
                <p>Notes: Data are expressed as median (md) and interquartile range (IQR), and categorical variables are expressed as frequency (%). The &#967;&#178; (chi-squared) test was used for the independent samples.</p>
              </fn>
              <fn id="TFN16">
                <label>*</label>
                <p>eGFR: estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD).</p>
              </fn>
              <fn id="TFN17">
                <label>&#8224;</label>
                <p>LVEF: Left Ventricular Ejection Fraction.</p>
              </fn>
              <fn id="TFN18">
                <label>&#8225;</label>
                <p>Lyse-CATHE (fibrinolysis-catheterization); ECG: electrocardiographic. Bold indicates statistical significance.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The KK functional classification showed good performance in predicting in-hospital mortality: AUC: [0.77 95% CI (0.73-0.81), p&lt;0.001] in the group with a score &#8805; II, showing better accuracy than the reperfusion angiographic scores: TIMI-Flow (3) and MBG (3), AUC: [0.69; 95% CI (0.64-0.75), p&lt;0.001], as well as a better performance when we stratified the patients, according to left ventricular ejection fraction, AUC: [0.52; 95% CI (0.47-0.58), p=0.34].</p>
          <p>Our study was careful to evaluate the performance of the prediction scores: TIMI-Risk, AUC: [0.79; 95% CI (0.75-0.84)], p&lt;0.001; GRACE, AUC: [0.82; 95% CI (0.78-0.86), p&lt;0.001]; Killip-Kimball AUC: [0.82; 95% CI (0.78-0.87), p&lt;0.001], (<xref ref-type="fig" rid="f5">Figure 2</xref>). For the Killip-Kimball categories, the following scores were obtained: positive likelihood ratio: 3.76; negative likelihood ratio: 0.33; and DOR (Diagnostic Odds Ratio): 11.39 for in-hospital mortality prediction rates, defined as the probability of patients in the functional class &#8805; II (II, III, IV) who died, relative to the probability of patients in the functional group &#8805; II who survived.</p>
          <fig id="f5">
            <label>Figure 2</label>
            <caption>
              <title>Prediction scores for in-hospital mortality. Note. The C-Statistics, ROC and AUC. TIMI-Risk, AUC: [0.79; 95% CI (0.75-0.84), p&lt;0.001]; GRACE-score, AUC: [0.82; 95% CI (0.78-0.86), p&lt;0.001]; Killip-Kimball, AUC: [0.82; 95% CI (0.78-0.87), p&lt;0.001].</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf02-en.tif"/></fig>
          <p>In a logistic regression model with covariance analyses, obesity, women, patients with diabetes mellitus, chronic renal failure, previous stroke, and the elderly were associated with the highest rates of fatal events (<xref ref-type="fig" rid="f6">Figure 3</xref>). The model fit presented a good predictive performance.</p>
          <fig id="f6">
            <label>Figure 3</label>
            <caption>
              <title>In-hospital mortality predictors. Note. Prediction variables in a binary logistic regression model, with OR-95% CI; and p-value.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-119-05-0691-11055-gf03-en.tif"/></fig>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>Even with the existence of many effective therapies, qualitative information is still lacking for stratification, notably in the pharmaco-invasive strategy, where the initial health assessment seems closely related to the prognosis. There are many approaches to risk stratification. Some are very complex and costly, but simple procedures can also be effective. In this light, the present study sought to provide descriptive epidemiological data on the different forms of acute ischemic symptoms, as well as show the applicability of some prediction scores in patients who received medical care mainly in basic health units and were subsequently referred to a tertiary university hospital for angiographic study and invasive procedures.</p>
        <p>Not every acute coronary syndrome shows classic signs or symptoms, such as the typical precordial or retrosternal pain, in turn delaying the diagnosis and therapeutic approaches, and impacting the prognosis. Thus, there is great interest in the major determinants of mortality and short-term complications after an acute myocardial infarction.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> In recent years, major advances in diagnosis and treatment have contributed to the decline in mortality due to coronary heart disease. In fact, efforts have been made for more active primary prevention, through a better control of risk factors, lifestyles, and pharmacological resources. Nevertheless, challenges regarding the prevention and treatment of cardiovascular diseases need to be widely available and applied without distinction.</p>
        <sec>
          <title>Clinical presentation and events in subgroups</title>
          <p>There is evidence of differences among genders in the application of technological advances.<sup><xref ref-type="bibr" rid="B12">12</xref>&#8211;<xref ref-type="bibr" rid="B15">15</xref></sup> In our analysis, symptoms referred to as dyspnea or syncopal episodes were significantly more prevalent in women, and were particularly relevant for this group, presenting higher mortality rates. Several multifactorial mechanisms have been proposed for the greater cardiac mortality of women. The explanations often include a smaller coronary diameter in females, lower collateral flow, predisposition to plaque erosion and distal embolization, and other phenotypic characteristics of atherosclerotic plaques.<sup><xref ref-type="bibr" rid="B16">16</xref>&#8211;<xref ref-type="bibr" rid="B18">18</xref></sup> Women generally present events approximately a decade later than men, notably in post-menopause, possibly due to an estrogenic decrease and a loss of protective effects, with a consequent worsening of risk factors, weight gain, and insulin resistance.<sup><xref ref-type="bibr" rid="B19">19</xref>&#8211;<xref ref-type="bibr" rid="B21">21</xref></sup> In our cohort, the delay in recognizing symptoms, possibly due to their atypical appearance, had an impact on temporal metrics for thrombolysis, such as those recorded in the group of women and diabetics.</p>
          <p>Diabetes is a potential risk factor in women. A meta-analysis to estimate the relative risk of fatal coronary heart disease associated with diabetes, involving approximately 450,000 patients, revealed a 50% higher relative risk in women.<sup><xref ref-type="bibr" rid="B22">22</xref></sup> The higher coronary risk associated with diabetes in women may reflect a treatment bias favorable to men. Studies show that men with diabetes or established cardiovascular disease are more likely to receive antiplatelet drugs, statins, or antihypertensive drugs than women.<sup><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref></sup> Additionally, there are reports of poor adherence to guideline recommendations in women, such as a longer door-to-balloon time.<sup><xref ref-type="bibr" rid="B25">25</xref>&#8211;<xref ref-type="bibr" rid="B28">28</xref></sup> It was also observed that males received fibrinolytic therapy earlier, possibly due to the clearer presentation of ischemic symptoms.</p>
          <p>The clinical appearance, defined above as dyspnea, was more prevalent in patients with previous infarctions, possibly due to additional myocardial impairment. The report of dyspnea was also noted in patients with diabetes. This may have had a significant impact on the mortality rate due to the absence of typical symptoms or warning signs.</p>
        </sec>
        <sec>
          <title>Risk scores</title>
          <p>Although there is no ideal stratification model, it should contain the following characteristics: easy implementation, objectivity, accuracy, and widespread use. Killip-Kimball, a functional classification method applied during first medical contact, was an important predictor for fatal outcomes during the hospital period, with a good negative predictive value. The index of the severity of cardiac insufficiency in patients with acute myocardial infarction was proposed by Thomas Killip and John Kimball in an attempt to measure the risk of in-hospital events and the potential benefit of the specific management of medical care provided in coronary care units. Our analysis highlights the clinical use of a physical examination as a simple tool without sophisticated technological requirements in order to identify signs of heart failure upon hospital admission, which played a relevant prognostic role in mortality rates for the hospital period, since the proportions of deaths and the distributions of survival data were significantly different within Killip-Kimball class &gt; I.</p>
        </sec>
        <sec>
          <title>Hospital mortality rates</title>
          <p>The mortality rate, including events during the angiographic procedure and those related to the index event, was associated with mechanical complications and severe and irreversible electrical disturbances. It has been reported that delays in recanalization time are associated with a greater impairment of ventricular function, microcirculation disturbances, and higher mortality rates.<sup><xref ref-type="bibr" rid="B29">29</xref></sup> It is interesting to note that our study found no association of mortality rates among patients in the group with lower left ventricular ejection fraction (LVEF) nor with the angiographic scores. In fact, totally occluded culprit lesion (TIMI-flow-0) proved to be unassociated with higher in-hospital mortality rates after STEMI treated with TNK, when compared to TIMI-flow &#8805;1. Moreover, malignant ventricular arrhythmias can appear earlier in ischemic processes and continue to be an expected cause of death in myocardial infarctions.<sup><xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup> In our cohort, in-hospital mortality rates were higher among patients with sustained malignant ventricular arrhythmias than among patients without sustained ventricular arrhythmias, defined as ventricular tachycardia or fibrillation. However, due to the observational characteristic of our study, several difficulties were encountered in characterizing the ventricular arrhythmias, especially in the post-angioplasty period, as the occurrence of these events was difficult to predict. Thus, it can be speculated that severe electrical disturbances could be a strong marker of in-hospital outcomes, despite the success of percutaneous coronary intervention and their respective angiographic scores, and they may not be correlated with LVEF as well. Presumably, it seems to be a better marker when applied to measure outcomes in the medium and long terms.</p>
          <p>Some subgroups of special interest were examined in their associations with mortality rates, such as women, obese patients, diabetics, and elderly individuals. In this sense, after myocardial infarction, women appear to be at a higher risk of reinfarction and death, which can be partially explained by the more advanced age, as observed in our study.</p>
          <p>By contrast, chronic kidney disease (CKD) represents an independent risk factor for the development of ischemic heart disease, increasing mortality with the advancement of renal impairment. Previous kidney damage to or as a consequence of infarction is associated with worse outcomes.<sup><xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref></sup> It is likely that there is a reciprocal relationship between the coronary atherosclerotic process and the renal function, and that the presence of coronary disease would be associated with a worsening of the renal function. CKD and cardiovascular disease are closely related, and the presence of one condition synergistically affects the prognosis of the other.<sup><xref ref-type="bibr" rid="B34">34</xref></sup> Our data express the highest mortality rates for these patients.</p>
          <p>Patients who had suffered a prior stroke also showed higher rates of fatal events, highlighting the need for prevention and adequate care for this subgroup.<sup><xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref></sup> The same concept may be applicable for elderly individuals, possibly due to the greater biological frailty in this group. The mechanisms for this relation seem to be multiple, involving anatomical, biochemical, and immunological characteristics, or even longer exposure to classic risk factors. Another finding in our cohort was the higher mortality rates in patients with diabetes mellitus, which is in agreement with previous studies.<sup><xref ref-type="bibr" rid="B37">37</xref>&#8211;39</sup> Diabetes mellitus is often associated with multiple mechanisms for cardiovascular disease, such as obesity, hypertension, renal failure, subclinical inflammation, endothelial dysfunction, and microvascular impairment. Nonetheless, no significant differences were found in either the TIMI-flow or the MBG reperfusion angiographic scores when comparing the groups of patients with and without diabetes.</p>
        </sec>
        <sec>
          <title>Strengths and limitations</title>
          <p>The present study has limitations. First, it was an observational study, with correction of known or measured confounding factors. Thus, we cannot conclude that the observed associations are causal. Furthermore, our records included only patients who underwent pharmaco-invasive intervention, disregarding those who were referred for primary percutaneous treatment or those who had formal contraindications for fibrinolysis. Given that the study was performed at a single university center, these standards of practice and results should be interpreted with caution. Another limitation of our study was the analysis of outcomes for the in-hospital period only. In an important sense, our internal validation indicated that the model fit was good and the diagnostic prediction models performed well in independently predicting the prognosis.</p>
        </sec>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusions</title>
        <p>Our data revealed higher in-hospital mortality rates in women; in patients with diabetes mellitus, obesity, CKD, and prior stokes; as well as in the elderly. The significant gender-related disparity persists in women, with delays in the recognition of symptoms of ischemia, and the immediate initiation of fibrinolytic therapy, thus favoring worse clinical results. The applicability of the Killip-Kimball score in accurately predicting fatal events should be highlighted, regardless of the clinical presentation of the acute ischemic event, measured upon the first medical contact, especially in the pharmaco-invasive strategy.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="supported-by" id="fn4">
          <p>
            <bold>Sources of Funding</bold>
          </p>
          <p>There were no external funding sources for this study.</p>
        </fn>
        <fn fn-type="other" id="fn5">
          <p>
            <bold>Study Association</bold>
          </p>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other" id="fn6">
          <p>
            <bold>Ethics approval and consent to participate</bold>
          </p>
          <p>This study was approved by the Ethics Committee of the Universidade Federal de S&#227;o Paulo under the protocol number CAAE: 38692514.1.1001.5505. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
